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Abstract 
Numerous members of the Major Facilitator Superfamily of membrane transporters are 
involved in multidrug resistance (MDR) of gram-positive bacteria, such as Staphylococcus 
aureus (S. aureus).  Genome data indicate that MDR transporters (MDT) constitute up to 1.0% 
of total cell proteins, but the majority remain uncharacterized: substrates, transport rates, and 
structures remain unknown (Forrest et al., 2011; Tsai and Ziegler, 2010; Ward et al., 2001).  
The main goal of this project was to develop a technique for substrate profile analysis and 
transport kinetics measurement of putative MDT from S. aureus, and other bacteria, using a 
well-characterized transporter, the multidrug facilitator A (MdfA), from Escherichia coli (E. 
coli), as a model protein.  To provide structural basis for drug transport and binding studies, we 
also conducted preliminary MdfA crystallization trials.  
MdfA was expressed and purified using a procedure previously established in our lab 
(O'Grady, 2010).  MdfA couples substrate transport across the cell membrane to the 
counterflow of protons.  To test substrate transport by MdfA, we developed an assay based on 
monitoring proton transport in membrane vesicles using 9-amino-6-chloro-2-methoxy acridine 
(ACMA), a pH-sensitive fluorophore. We confirmed MdfA activity in membrane vesicles by 
this assay.  In proteoliposomes containing co-reconstituted MdfA and FoF1 ATPase, addition of 
ATP generates a transmembrane pH gradient, which can be used as the driving force for MdfA-
mediated substrate transport.  Substrate binding to MdfA was investigated by nuclear magnetic 
resonance (NMR) experiments with 13C-labeled chloramphenicol. We observed specific 
interactions between chloramphenicol, a known MdfA substrate, and MdfA with an estimated 
dissociation constant (Kd) on the order of 10 µM.  Detergents that have been previously 
successfully used for structural studies of membrane proteins by NMR and X-ray 
crystallography were tested for structural studies of MdfA.  We determined that MdfA is active; 
however, further work is required to optimize the substrate profile assay, confirm substrate-
binding data, and obtain crystals suitable for structural studies.  
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1. Introduction 
Membrane transport proteins are highly relevant to human physiology and disease.  In 
fact, two of the most highly prescribed drugs in the world, fluoxetine (Prozac) and omeprazole 
(Prilosec), are targeted to transporters (Abramson et al., 2003).  On the other hand, the 
simultaneous emergence of resistance in eukaryotic and prokaryotic cells to many chemically 
unrelated drugs, referred to as MDR, is also related to membrane transport proteins (Adler and 
Bibi, 2002).   
MDR was first observed in the 1950s and 60s among bacteria such as Shigella, 
Salmonella, and E. coli, in the developing world (Levy and Marshall, 2004; Watanabe, 1963).  
At that time, MDR was not considered to be a problem for industrialized countries; however, 
since the 1970s, when drug resistance was observed in Haemophilus influenzae and Neisseria 
gonorrhoeae, healthcare providers and scientists have begun to acknowledge this area as one of 
growing concern (Levy and Marshall, 2004; Rice, 2010; Watanabe, 1963).  Today, MDR 
pathogens are most commonly observed in healthcare settings, and include methicillin-resistant 
S. aureus (MRSA), vancomycin-resistant Enterococcus species, extended-spectrum β-
lactamase producing E. coli and Klebsiella species, fluoroquinolone- or carbapenem-resistant 
Enterobacteriaceae and Pseudomonas aeruginosa (P. aeruginosa) and MDR Mycobacterium 
tuberculosis (Levy and Marshall, 2004; Rice, 2010; Watanabe, 1963).  In Europe, half of all 
deaths from clinical infection are associated with MDR bacteria (Coates, 2011).  In the United 
States and the United Kingdom, 40-60% of nosocomial S. aureus strains are MRSA and usually 
MDR.  Treatment of MRSA involves the use of vancomycin, but in recent years, vancomycin-
resistant strains of S. aureus have appeared, leading to treatment failure.  It is estimated that, 
depending on the number of deaths, treatment of patients with MRSA alone costs up to $30 
billion (USD) annually.  This medical and financial burden is likely to grow as the frequency of 
drug resistance rises and extends beyond hospital walls: resistant pathogens are now 
increasingly being traced from the community to the hospital (Levy and Marshall, 2004).   
Drug resistance emerges when two components come together in an environment or 
host: the antibiotic or antimicrobial, which inhibits susceptible organisms and selects those 
most resistant, and the genetic resistance determinant in pathogens selected for by the 
antimicrobial drug.  The density of antibiotic usage enhances resistance selection and its effects 
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(Levy and Marshall, 2004).  Bacteria can become resistant to drugs by acquiring the gene for a 
resistant trait via mobile genetic elements; acquiring sequential mutations in chromosomes 
leading to resistance genes; or an increase in the expression of membrane proteins that pump 
drugs out of the cell (Fig. 1.1) (Krulwich et al., 2005; Levy and Marshall, 2004; Watanabe, 
1963).  These resistance mechanisms are reviewed in detail later.  Curtailing widespread 
antibiotic use has been shown to reduce and sometimes reverse drug resistance levels.  
However, as agents and strategies were developed to overpower specific resistance to drugs, 
multidrug resistance caused by active efflux was increasingly observed (Fig. 1.1) (Coates, 
2011; Cook et al., 1989; Gootz, 2010; Levy and Marshall, 2004; Nikaido, 1994; Rice, 2010).  
Some drug efflux transporters are substrate specific, while MDT can transport a variety of 
structurally unrelated compounds (Li and Nikaido, 2004). 
In fact, active drug efflux by membrane transporters greatly enhances the intrinsic 
resistance of bacteria (Edgar and Bibi, 1999; Hancock, 1997; Markham and Neyfakh, 2001; 
Nikaido, 1994).  This is especially critical for gram-positive bacteria and mycobacteria, which 
lack the poorly permeable outer membrane of their gram-negative counterparts, and as a result, 
rely on drug efflux for survival against toxic compounds (Almeida da Silva et al., 2011; 
Markham and Neyfakh, 2001).  In other cases, the major advantage of these transporters is in 
maintaining subtherapeutic intracellular drug concentrations, allowing for the selection of other 
resistance mechanisms which are unrelated to active efflux (Doleans-Jordheim et al., 2008; 
German et al., 2008; Markham and Neyfakh, 1996).  
Antibiotic efflux was first observed in 1980, when it was recognized as a mechanism for 
tetracycline resistance in enterobacteria (McMurry et al., 1980).  Since then, efflux has been 
observed in virtually every living system, and efflux-based antibiotic resistance is increasing 
(Adler and Bibi, 2002; Fluman and Bibi, 2009; Forrest et al., 2011; Li and Nikaido, 2004; Li 
and Nikaido, 2009).  In particular, efflux of multiple drugs by a single transporter is of 
significant medical and biochemical interest.  While advances in developing strategies against 
transporters implicated in MDR are being made, there is a need for methods that can 
demonstrate and characterize drug efflux pumps both in the lab and in the clinic (Viveiros et 
al., 2008).  The goal of this project is to use MdfA, a model E. coli MDT of the Major 
Facilitator Superfamily (MFS), to develop universal methods for structural and functional 
characterization of putative MDT from MRSA. 
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Figure 1.1. Mechanisms of bacterial antibiotic resistance.  Antibiotic resistance can arise in 
a bacterial cell by one or more of the following mechanisms: 1. Inactivation of the antibiotic 
by chemical modification or breakdown; 2. Rapid efflux of the antibiotic, preventing an 
effective level of the compound from reaching its target; 3. Modification or replacement of 
the original target so that it is no longer sensitive to the antibiotic (not shown); or 4. 
Changes in the bacterial cell surface that reduce antibiotic uptake (not shown).  Reproduced 
from Levy and Marshall (2004) with the permission of the publisher.   
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2. Background and state of the problem 
2.1. Multidrug resistance in bacteria 
2.1.1 Mechanisms of drug resistance in bacteria 
When a drug is introduced to the external medium of a bacterial cell, it must first cross 
the cell wall, in gram-positive bacteria, or the outer membrane, in gram-negative bacteria, 
before it can permeate the cell membrane and exert its action.  The mesh of the peptidoglycan 
cell wall of gram-positive bacteria is too coarse to offer much resistance to the diffusion of 
small molecules such as antibiotics.  The outer membrane of gram-negative bacteria is much 
more impermeable, since it is composed of less fluid lipopolysaccharide, and as a result, drug 
penetration into the cell is hindered (Nikaido, 1994).  Once a drug has passed the cell wall or 
outer membrane, it crosses the cell membrane. From the inner membrane leaflet, the drug can 
diffuse into the cytosol and find its target (Mazurkiewicz et al., 2005).  It is clear that even the 
most effective permeability barrier cannot completely shut out the influx of small molecules 
(Hancock, 1997; Markham and Neyfakh, 2001; Nikaido, 1994).  As the cell’s first line of 
defense against an antibiotic fails, those cells with specific resistance mechanisms will be 
selected (Nikaido, 1994).  
Antibiotic resistance can arise in a bacterial cell by one or more of the following 
mechanisms (Fig. 1.1) (Krulwich et al., 2005).  First, changes in the bacterial cell surface can 
drastically affect antibiotic uptake.  Antibiotics in gram-negative bacteria are often taken up 
using porins that are non-specific for small molecules (Nikaido, 1989).  For example, in gram-
negative bacteria such as P. aeruginosa, changes in the outer membrane porins affect drug 
uptake (Angus et al., 1982).  Kropinski and coworkers were able to show that alterations in the 
lipopolysaccharide composition of the outer membrane of P. aeruginosa influenced the number 
of open functional pores, and could therefore enhance or decrease antibiotic susceptibility in 
this bacterium (Kropinski, 1982).     
Second, the antibiotic may be deactivated by enzymatic modification, as is commonly 
the case for aminoglycosides (Fig. 1.1) (Shi et al., 2011).  Aminoglycosides can be 
phosphorylated, adenylated, or acetylated, leading to reduced target binding to the ribosome, 
and increased survival of the bacterial cell (Alekshun and Levy, 2007; Shi et al., 2011).   
Third, the antibiotic target may be modified so that it is no longer sensitive to the 
antibiotic itself, as seen in the case of erythromycin.  Erythromycin binds to the 50S ribosomal 
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subunit and prevents peptide elongation (Sköld, 2011).  Erythromycin resistance in S. aureus is 
caused by methylation of an adenine residue in the 23S rRNA subunit, which results in a 
conformational change that abolishes erythromycin binding (Lai, 1971; Sköld, 2011).   
Finally, active efflux of the antibiotic from the cell, preventing a drug from reaching its 
target at an effective concentration, is a significant and ubiquitous form of antibiotic resistance 
(Fig. 1.1) (Krulwich et al., 2005).  In E. coli, for example, AcrAB (discussed in more detail 
below), has been identified as a major pump responsible for resistance to such antibiotics as 
tetracycline, chloramphenicol, ampicillin and rifampin (Okusu et al., 1996).   
 
2.1.2 Bacterial multidrug transporters  
MDT, efflux pumps that transport a variety of cytotoxic compounds out of the cell, are 
found among all the major categories of bacterial membrane transporters that have been 
characterized on the basis of sequence homology (Lewinson et al., 2006; Saier and Paulsen, 
2001).  MDT from five transporter families have been identified: ATP-binding cassette (ABC) 
transporters; multidrug and toxic compound exporters (MATE); small MDR (SMR) 
transporters; resistance-nodulation-division (RND) transporters; and MFS transporters (Fig. 
2.1) (Saier and Paulsen, 2001).  The first four families listed here will be described in this 
section, while details regarding members of the MFS will be described in section 2.2.   
 Members of the ABC superfamily typically transport a diversity of substrates such as 
inorganic ions, amino acids, and polypeptides (Higgins, 2007).  MDT from this family, 
however, can each transport a diversity of structurally diverse, lipophilic substrates: in human 
cancer patients, MDR1 (also known as P-glycoprotein), confers resistance to such 
chemotherapeutics as doxorubicin, Taxol and etoposide, and in other organisms ABC MDT 
have been shown to confer resistance to antibiotics, antifungals and herbicides (Higgins, 2007, 
2004; Ramachandra et al., 1998).  ABC transporters are composed of four domains: two 
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Figure 2.1. Bacterial drug and multidrug transporters.  The ABC transporters use the energy 
from ATP hydrolysis to actively extrude drugs from the cell, while the members of the 
MFS, MATE, SMR and RND families use secondary energy sources in the form of a proton 
or sodium motive for active drug efflux.  Reproduced from Krulwich et al. (2005), with the 
permission of the publisher.     
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transmembrane domains (TMD) and two nucleotide-binding domains (NBD) (Fig. 2.2).  The 
recently solved structure of Sav1866, an ABC MDT from S. aureus, defined critical structural 
elements of these transporters.  The ATP-binding site is located at the interface of the NBD 
(Fig. 2.2) (Dawson and Locher, 2006).  Specialized “coupling helices” couple the 
conformational changes associated with ATP-binding, hydrolysis, and release to the export of 
drugs by drawing the TMD closer together, and shifting their conformation from inward-facing 
to outward-facing (Dawson and Locher, 2006; Locher, 2009; van Veen et al., 2000).  The 
precise location of the substrate-binding site remains elusive, but is likely located at the 
interface of the TMD (Fig. 2.2) (Dawson and Locher, 2006; Higgins, 2004).   
 The SMR family is composed of over 250 members and is represented by EmrE of E. 
coli (Adam et al., 2007; Li and Nikaido, 2009).  EmrE is a proton/cation antiporter, shown to 
export such toxic substrates as ethidium, tetraphenylphosphonium (TPP+), erythromycin, and 
methyl viologen (Fig. 2.3) (Paulsen et al., 1996; Rotem and Schuldiner, 2004).  This small 
transporter functions as an antiparallel homodimer, each composed of four α-helices, which 
essentially form a pathway that is alternately accessible from either side of the plasma 
membrane (Fig. 2.3) (Butler et al., 2004; Chen et al., 2007; Higgins, 2007; Korkhov and Tate, 
2009).  The unusual dimer structure of SMR transporters has been a matter of considerable 
debate, but evidence now indicates that all SMR transporters, whether homo- or heterodimers, 
form in an antiparallel orientation (Fig. 2.3) (Chen et al., 2007).  E14 is the only membrane 
embedded charged residue, and the E14s from each monomer face the substrate-binding pocket 
(Chen et al., 2007; Weinglass et al., 2005).  E14 is essential for both substrate binding and 
proton translocation; the stoichiometry of transport is 2 H+/substrate (Adam et al., 2007; 
Soskine et al., 2004).  However, it is likely that EmrE binds substrates not only by charge 
interactions, but also by cation/π interactions between positively charged substrates and 
aromatic residues in the binding pocket (eg. W63) (Adam et al., 2007; Dougherty, 1996).  This 
type of non-covalent interaction is able to compete with solvation; as a result, it creates binding 
sites that are at once both polar and hydrophobic (Dougherty, 1996).  Though biochemical 
evidence suggests that this is the case, a high-resolution structure of the native substrate-bound 
EmrE is required before the exact mechanism of substrate binding can be understood.   
The tripartite MDT from the RND family are extremely efficient at extruding drugs 
across both membranes of gram-negative bacteria (Fluman and Bibi, 2009).  These transporters  
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are expressed constitutively in the cell, contributing significantly to the intrinsic resistance of 
bacteria (Murakami et al., 2006; Nikaido, 1998).  They have an extraordinarily broad substrate 
range, and are able to transport a variety of toxic compounds including drugs such as 
chloramphenicol, aminoglycosides, erythromycin and tetracycline, organic solvents, 
Figure 2.2. Ribbon diagram of Sav1866, an ABC multidrug transporter from S. aureus.  The 
subunits of the homodimer are colored yellow and turquoise.  Bound ATP is shown in ball-
and-stick representation.  The grey box indicates the probable location of the membrane 
bilayer.  The substrate binding site is thought to be located at the interface of the two TMDs 
(indicated by an arrow).  Reproduced from Dawson and Locher (2006), with the permission 
of the publisher.  
 
Figure 2.3.  Ribbon representation of EmrE-TPP+ dimer.  One monomer is in gradient and 
the other is in gray.  Bound TPP+ is colored red.  The membrane bilayer is indicated in gray.  
Reproduced from Chen et al., (2007) with the permission of the publisher.    
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isoflavenoids, fatty acids, bile salts, and steroids (Fig. 2.4) (Lomovskaya et al., 2007; Saier and 
Paulsen, 2001; Zgurskaya and Nikaido, 2000).  One of the most well-studied RND systems is 
AcrAB-TolC from E. coli (Li and Nikaido, 2004).  AcrB is a transmembrane protein with 12 
TMH, the functional unit of which is a trimer (Fig. 2.4) (Higgins, 2007).  It is a member of the 
RND family, and is the component responsible for substrate binding and specificity (Murakami 
et al., 2006).  RND transporters in gram-negative bacteria function with a periplasmic protein 
from the membrane fusion family, in this case, AcrA, and an outer membrane channel from the 
outer membrane factor family, in this case, TolC, to pump substrates across two membranes 
(Lomovskaya et al., 2007).  It is interesting to note that RND systems have also been shown to 
export drugs from the periplasm and show synergy with single component pumps in order to 
enhance their effectiveness (Li and Nikaido, 2004; Tal and Schuldiner, 2009).  Transport by 
AcrAB-TolC occurs by a peristaltic movement.  Each of the three AcrB monomers has a 
binding site that alternates between three states sequentially: access, binding and release.  The 
large binding site is lined by hydrophobic and aromatic amino acids, and also has two polar 
residues, Q176 and N274, which neutralize the charge of cationic substrates, likely by hydrogen 
bonding.  It is thought that the aromatic residues interact with substrates by hydrophobic or 
stacking interactions.  The substrate-binding site allows multisite binding, evidenced by the 
binding of both minocycline and doxorubicin to the same cavity, in different, but overlapping 
locations.  Binding and extrusion of substrates is based on steric considerations; substrates are 
essentially squeezed out of the binding site by conformational changes induced by the 
movement of protons down the electrochemical gradient (Murakami et al., 2006).  Essentially, 
energy is transduced mediated by conformational changes from one domain to a another 
domain that then mediates drug transport through changes in the affinity and orientation of the 
binding site (Higgins, 2007).   
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Members of the MATE family are less well studied.  They are represented by NorM of 
Vibro parahaemolyticus and confer resistance to multiple cationic agents, including 
fluoroquinolones, as proton and sodium antiporters (Kuroda and Tsuchiya, 2009).  The use of  
a sodium gradient as an energy source is of biochemical interest (Kuroda and Tsuchiya, 2009).  
All MDT substrate binding pockets, therefore, appear to have similar properties: a large, 
flexible binding cavity rich in polar and aromatic residues, which not only provides overlapping 
binding sites, but also allows for binding at different orientations and locations (Lewinson et 
al., 2006; Sennhauser et al., 2009).  MDT are polyspecific: they interact with many dissimilar 
substrates with varying affinities, and do not interact with others at all (Lewinson and Bibi, 
2001).  Neyfakh explains multidrug binding elegantly.  Briefly, proteins binding hydrophobic 
ligands do not have to compete with water molecules for substrate binding, as is the case with 
hydrophilic substrates.  Comparable binding affinity can be achieved by simply creating a 
hydrophobic environment within the binding site, and this affinity can be enhanced by 
electrostatic attraction to charged residues within the site.  In other words, for these proteins, 
ligand specificity is not an inherent property of the binding mechanism.  Specificity would 
simply stem from the geometry of the binding site (Neyfakh, 2002).  This agrees with other 
findings that for MDT, three factors affect binding: hydrophobicity, charge, and shape 
Figure. 2.4. Ribbon representation of the AcrB trimer.  Bound substrate, minocycline, is 
indicated as “drug” in the figure.  TolC and AcrA are not shown in this figure.  Reproduced 
from Murakami et al. (2006), with the permission of the publisher.  
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(Zgurskaya and Nikaido, 2000).  Indeed, most MDT substrates are hydrophobic and have at 
least one aromatic moiety (Fluman and Bibi, 2009).  MDT from different families have 
overlapping substrate specificities and are inhibited by the same molecules; no family-specific 
resistance profile has been observed (Krulwich et al., 2005; Putman et al., 2000).  In fact, MDT 
mediated resistance is observed against all important classes of antibiotics (Putman et al., 
2000).   
 The broad substrate specificity of MDT has raised questions about their effect on 
normal cellular metabolites.  To date, evidence implicating MDT in the efflux of essential 
cellular metabolites has not been found, though this might simply be a result of the tight 
regulation of MDT and low endogenous expression levels (Fluman and Bibi, 2009; Li and 
Nikaido, 2004).  It is important to note that most molecules normally present in the cytosol are 
too hydrophilic to bind with significant affinity to the hydrophobic binding site of an MDT 
(Fluman and Bibi, 2009).  However, there is some evidence for the involvement of MDT in 
virulence, indicating that some MDT transporters do transport cellular products (Li and 
Nikaido, 2009).  Furthermore, other MDT have been implicated in removal of excess toxic 
normal metabolites, and in alkalitolerance (Helling et al., 2002; Krulwich et al., 2005; 
Lewinson et al., 2004).  Thus it would seem that MDT have specific and beneficial effects in 
cellular processes in addition to their function in resistance.  
 The question of which effects of MDT represent true physiological functions, and which 
are simply opportunistic, has not yet been resolved.  Studies of MDT at endogenous expression 
levels often show that they do not greatly alter the drug susceptibility profile of the bacterium 
(Fluman and Bibi, 2009).  Since antibiotic resistance depends on genes that are either 
chromosomally encoded or encoded on mobile genetic elements, it has been proposed that these 
genes have been retained during evolution because MDT have primary functions that are 
unrelated to their drug extrusion capabilities (Krulwich et al., 2005; Lewinson et al., 2004; 
Lewinson et al., 2006; Neyfakh, 1997; Paulsen et al., 2000).  However, the fact that MDT are 
present in all kingdoms of life and are ancient suggests that organisms had to move lipophilic 
toxic chemicals all the time, and it is therefore possible that efflux of endogenous compounds is 
a trait that was acquired later in evolution (Li and Nikaido, 2004; Sköld, 2011).  Many bacteria 
with large percentages of drug resistance pumps live in environments where natural biological 
warfare might be present, while others inhabit host species that produce chemicals toxic to 
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bacteria (Li and Nikaido, 2004; Li and Nikaido, 2009; Neyfakh, 1997; Paulsen et al., 2000).  
While this debate is unlikely to be resolved in the near future, it is important to recognize that 
the clinical importance of MDT lies largely in providing a broad and effective resistance 
mechanism to bacterial pathogens (Markham and Neyfakh, 2001). 
   
2.2. Structure and mechanism of MFS transporters 
2.2.1 General features of MFS transporters 
The MFS is a well-characterized, large and diverse superfamily that includes over 1000 
members from all kingdoms (Saidijam et al., 2006).  MFS proteins typically range in size from 
400-600 amino acids, with 12-14 transmembrane helices (TMH) (Law et al., 2008).  At the 
superfamily level, MFS members share low sequence similarity and are united only by a pair of 
conserved signature sequences, DRXXRR, at equivalent positions on the N- and C-terminal 
halves of the proteins (Law et al., 2008).  The superfamily comprises 28 related families that 
catalyze substrate transport by uniport, symport, or antiport (Kaback et al., 2001).   
In bacteria, MFS proteins generally outnumber other membrane transporters (Saidijam 
et al., 2006).  Transport is energized by a secondary energy source, either a proton, sodium, or 
other substrate gradient (Saidijam et al., 2006).  Individual members of the MFS can show 
stringent specificity, yet as a group, the superfamily accepts an enormous diversity of substrate 
types including ions, sugars, nucleosides, drugs, amino acids, bile salts, and vitamins (Law et 
al., 2008; Saier, 2000).  This phenomenon is readily explained by the observation that 
substitution of a few key amino acid residues in the substrate-binding site of several MFS 
proteins can change the specificity of the transporter while retaining the transport mechanism 
(Huang et al., 2003).  
 Membrane proteins present a particular challenge to structural and functional studies 
due to their hydrophobicity, flexibility, and relative instability (Carpenter et al., 2008).  
However, diligent efforts have resulted in several well-characterized systems that help shed 
light on the general characteristics of the family.  In fact, structural studies of MFS proteins 
show that even when sequence homology between individual transporters is low, the overall 
fold is conserved (Law et al., 2008; Sigal et al., 2005).  Two model systems in the MFS are 
LacY and GlpT of E. coli.  LacY is a 417 amino acid long symporter that catalyses the uptake 
of galactosides using the free energy released from the downhill translocation of protons 
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(Abramson et al., 2004).  GlpT, a 452 amino acid long antiporter, exchanges glycerol 3-
phosphate (G3P) for inorganic phosphate (Pi), using the Pi gradient as an energy source 
(Hayashi et al., 1964).  
The first atomic resolution structures of MFS transporters, those of LacY and GlpT, 
were solved in 2003 (Fig. 2.5) (Abramson et al., 2003; Huang et al., 2003).  The structures 
revealed monomers with 12 TMH, with several α-helices protruding beyond the membrane 
surface on the cytoplasmic side (Fig. 2.5).  Interestingly, both LacY and GlpT were solved in an 
inward facing conformation, revealing a large, hydrophilic internal cavity, open toward the 
cytoplasm, but completely closed from the periplasm (Fig. 2.5).  The cavity is equidistant from 
both sides of the membrane, at the interface between two domains, one N-terminal and the 
other C-terminal (Abramson et al., 2004; Abramson et al., 2003; Huang et al., 2003).  The N- 
and C-terminal domains consist of six-helix bundles, have the same topology, and are related 
by an approximate two-fold symmetry (Abramson et al., 2003; Huang et al., 2003).   
 Wild type LacY was mutated to trap this flexible protein into a single substrate-bound 
conformation.  Thus the C154G mutant of LacY, which does not catalyze transport but binds 
substrate with high affinity, was solved in the presence of the lactose homolog, β-D-
galactopyranosyl-1-thio-β-D-galactopyranoside (IPTG) (Fig. 2.5A).  Its hydrophilic cavity is 
formed between helices I, II, IV, and V of the N-terminal domain, and helices VII, VIII, X, and 
XI of the C-terminal domain, while the remaining helices are embedded in the membrane.  
However, the sugar-binding site is only composed of helices I, IV, V, VII, and IX.  Abramson 
and coworkers noted that a major portion of the substrate binding site involved in substrate 
specificity is on the N-terminal domain, while the residues involved in substrate binding 
affinity, but likely have little to do with specificity, are located in the C-terminal domain 
(Abramson et al., 2003).  R144 (helix V), E126 (helix IV), and E269 (helix VIII) all interact 
with various oxygen atoms on the galactopyranosyl ring (Fig. 2.6) (Abramson et al., 2003; Nie 
et al., 2006).  W151 (helix V) is irreplaceable for sugar binding, and stacks hydrophobically 
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with the galactopyranosyl ring.  Other important residues include H322 (helix X), E325 (helix 
X), R302 (helix IX), and W236; these are all thought to be involved directly in proton 
translocation.  In fact, H322 may be the proton donor to E325, and R302 may interact with 
E325 to drive deprotonation (Fig. 2.6) (Nie et al., 2006).  
Figure 2.5. Ribbon representations of C154G mutant of LacY (A) and wild type GlpT (B).  
Both structures were solved in an inward-facing conformation.  LacY was solved with 
IPTG, a lactose analog, bound (black).  Top, both structures revealed N- and C-terminal α-
helical bundles, with hydrophilic cavities located at the interface of the bundles.  Bottom, 
helical organization of both proteins is the same, with the substrate binding sites formed by 
helices 1, 2, 4, and 5 (I, II, IV, and V) of the N-terminal bundle and 7, 8, 10 and 11 (VII, 
VIII, X and XI) of the C-terminal bundle.  Substrate transport is proposed to occur by a 
rocker-switch mechanism that involves the rotation of these bundles to allow alternate 
access of the central cavity to either side of the cell membrane.  Reproduced from 
Abramson et al. (2003) and Huang et al. (2003) with the permission of the publisher. 
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As in LacY, the hydrophilic cavity of GlpT is formed between helices I, II, IV, V, and 
helices VII, VIII, X and XI (Fig. 2.5B) (Huang et al., 2003).  However, since GlpT was not 
solved in its substrate-bound form, less is known about its binding site.  Previous biochemical 
studies have indicated that substrate binding and transport are mediated by the phosphate 
moiety of G3P, suggesting a positive surface electrostatic potential in the GlpT substrate-
binding site (Auer et al., 2001; Huang et al., 2003).  Huang and coworkers therefore suggest 
that the substrate-binding site is located at the closed end of the central cavity in the middle of 
the membrane (Fig. 2.5B) (Huang et al., 2003). Two positively charged residues, R45 and 
R269, are located at the proposed binding site, and docking experiments have confirmed that 
G3P is coordinated by these residues (Fig. 2.7) (Huang et al., 2003; Lemieux et al., 2004).  
While these residues are conserved in another bacterial sugar-phosphate/anion transporter, 
UhpT, these residues are generally not conserved in other MFS proteins, suggesting that they 
are specific to the sugar-phosphate/anion transporter subfamily (Auer et al., 2001; Huang et al., 
2003).   
Figure 2.6. Putative mechanism of lactose transport by LacY. N- and C-terminal domains 
are shown as yellow ovals. Key residues are labeled; hydrogen bonds are shown as blue 
lines. The proton and the substrate are shown as red and green circles, respectively; the 
hydrophilic cavity is represented as a light blue area Reproduced from Abramson et al. 
(2003) with the permission of the publisher.  	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Since the hydrophilic cavity is located between the N- and C-terminal domains of both 
proteins, it is likely that the structural change between inward- and outward-facing 
conformations involves rotation between these domains around an axis parallel to the 
membrane.  Biochemical data, in combination with the crystal structure, allowed for the 
production of a model of LacY in the outward-facing conformation.  A ~60° rotation between 
the N- and C-terminal domains reveals conformations that allow for the substrate binding site to 
be alternatively accessible from both sides of the membrane.  It is thought that tight closure of 
the binding site is obtained by flexibility in the helices lining the hydrophilic cavity (Abramson 
et al., 2003).  Indeed, glycine and proline residues in these helices cause kinks and bends not 
found in helices that are not involved in substrate binding (Abramson et al., 2004; Abramson et 
al., 2003).  In contrast, the helices in GlpT are less distorted and do not have any kinks.  
However, superposition of the structures of LacY and GlpT show that some GlpT helices have 
bends in regions that overlap with the kinks in LacY.  The bends in GlpT are also caused by a 
high glycine and proline content.  It is thought that these irregular helices provide the structural 
flexibility required to catalyze transport by a rocker-switch mechanism (Abramson et al., 2004). 
 The crystal structures of both LacY and GlpT suggest a rocker-switch mechanism of 
substrate transport (Fig. 2.5) (Abramson et al., 2003; Huang et al., 2003).  In order to 
understand the transport mechanism, it is necessary to identify crucial side chains, delineate 
their function and relationship to one another, and acquire structural and dynamic information 
Figure 2.7. Schematic drawing of central helices H1 and H7 of GlpT in inward (Ci) and 
outward (Co) conformations. Other helices are omitted for clarity. Rocker- switch–type 
movements of the helices that occur upon substrate binding allow the substrate-binding site, 
which comprises R45 and R269, to switch between the two sides of the membrane.  
Reproduced from Huang et al. (2003) with the permission of the publisher. 
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at the level of helix packing in the context of ion binding and release, as well as interactions 
between ions and the substrate (Adam et al., 2007; Kaback et al., 2001).  A combination of 
molecular biological and structural techniques has provided some clues to the mechanism used 
by MFS transporters (Kaback et al., 2001; Law et al., 2007).  Substrate binding to both LacY 
and GlpT leads to widespread conformational changes that allow for transport (Law et al., 
2007; Nie et al., 2006).  Nevertheless, only a few residues appear to be involved in substrate 
binding and translocation (Kaback et al., 2001; Nie et al., 2006; Yerushalmi and Schuldiner, 
2000).    
 Due to the reversibility of substrate transport by LacY, it has long been thought that the 
most likely trigger for turnover is substrate binding and dissociation on either side of the 
membrane (Fig. 2.8) (Kaback et al., 2001).  Transport consists of six steps, as described in 
figure 2.8.  The C154G LacY structure corresponds to step 4 in the transport cycle (Figs. 2.5A, 
2.6D, 2.8).  A comparison of the thermodynamics of substrate binding and transport catalysis 
by C154G and wild type (WT) LacY confirmed that the C154G mutant has tighter helix 
packing, providing an explanation for its increased thermostability, decreased tendency for 
aggregation, and inability to catalyze substrate transport.  The N- and C-terminal domains in the 
C154G mutant cannot rotate against each other, thus preventing substrate transport.  In fact, 
while both mutant and WT LacY have similar free energies of binding, the relative 
contributions of enthalpy and entropy vary greatly.  C154G LacY has a large negative value of 
ΔH and a negative value of TΔS.  A negative change in the entropic free energy component is 
related to H-bond formation, or a decrease in the number of isoenergetic conformations.  In 
other words, a specific conformer of C154G LacY is selected from the ensemble of 
conformations upon substrate binding.  This prevents the protein from overcoming the energy 
barrier to achieve the outward facing conformation.  WT LacY, on the other hand, is a highly 
dynamic protein that experiences widespread conformational changes upon substrate binding.  
Given the increase in entropic free energy associated with substrate binding, it is likely that the 
number of conformers for ligand-bound WT LacY is greater than that of free protein.  As a 
result, substrate-bound WT protein is able to catalyze transport by sampling different 
conformations.  The critical interactions in this process are salt bridges alternatively formed 
between R144 and E126 and E269 (Fig. 2.6) (Nie et al., 2006).    
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Substrate transport by GlpT can also be broken down into six discrete steps (Fig. 2.8). 
The X-ray structure of GlpT corresponds to the inward, substrate-free conformation, step three 
in the transport cycle (Figs. 2.5B, 2.8).  While structural data for the substrate-bound form is 
lacking, evidence from other studies provides insight into the antiport mechanism.  Phosphate 
binding pulls R45 and R269 together, moving the N- and C-terminal domains closer and 
narrowing the cytoplasmic pore (Fig. 2.7) (Huang et al., 2003).  Substrate binding further 
destabilizes the interface between the N- and C-terminal domains on the periplasmic side and 
allows tilting of the two domains to expose the substrate-binding site to the periplasm, yielding 
the outward-facing conformation (Lemieux et al., 2004). 
 The GlpT and LacY structures and corresponding mechanisms have been proposed to 
be a paradigm for all MFS transporters.  It is likely that all members of the MFS, be they 
Figure 2.8.  Substrate transport by LacY and GlpT.  Both transporters are thought to 
transport substrates in six discrete steps, starting with the outward facing conformation (Co).  
Ci refers to the inward, cytoplasm, facing conformation.  LacY is a symporter that uses the 
proton gradient (H) to drive galactoside (S) transport into the cell in a 1:1 stoichiometric 
ratio.  GlpT is an antiporter, and exchanges Pi for G3P.   	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uniporters, sympoters, or antiporters, operate by lowering the energy barrier between inward- 
and outward-facing conformations by binding substrate.  As a result, a substrate or ion gradient 
can drive transport for any of these processes (Lemieux et al., 2004).  
 
 
2.2.2 Energetics of substrate transport by MFS transporters 
 
Biological membranes have two complementary functions: first, to serve as a barrier for 
uncontrolled diffusion; and second, to provide channels and pumps for specific transport 
processes, such as ion and nutrient transport, toxin extrusion, and energy generation (Nelson, 
2008).  All living cells possess an energy-transducing membrane, composed of a phospholipid 
bilayer, and proteins, together with smaller amounts of associated carbohydrates (Nicholls, 
1982; Stein, 1990).  The essential feature of the lipid bilayer is that it has a hydrophilic exterior 
and a hydrophobic interior (Nelson, 2008).  Energy-transducing membranes have an inherently 
high electrical resistance and can also withstand high electric fields (Nicholls, 1982).  ATP 
synthase converts the energy of the electrochemical ion gradient into the chemical energy 
stored in the phosphoanhydride bond of the ATP molecule (Forrest et al., 2011; Nicholls, 
1982).    Proton or sodium pumps in the respiratory or photosynthetic electron transport chains 
replenish the ion gradients (Forrest et al., 2011; Nicholls, 1982).  Maintaining the concentration 
of ATP in disequilibrium with its hydrolysis products, ADP and Pi, allows ATP to be used to do 
work in the cell (Nicholls, 1982).   
The transport of most solutes across a membrane is catalyzed by membrane proteins 
(Abramson et al., 2003; Kaback et al., 2001).  Biochemical and phylogenetic analyses have 
revealed that up to 10% of total protein encoded in the bacterial and human genomes are 
transporters (Abramson et al., 2004).  This is not surprising considering that biochemical 
pathways are dependent on a balance of transport reactions: the import of exogenous substrates 
and the export of metabolic end products (Paulsen et al., 2000).  There are four main classes of 
transporters, classified on the basis of mode of transport and energy coupling source: channels, 
primary transporters, secondary transporters, and group translocators (Saier, 2000).  Channels 
use facilitated diffusion through a transmembrane pore (Paulsen et al., 2000).  
Primary and secondary active transporters use the energy of ATP or an ion 
electrochemical gradient, respectively, to catalyze the thermodynamically unfavorable transport 
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of a substrate against its electrochemical gradient (Abramson et al., 2004; Paulsen et al., 2000; 
Saier, 2000).  Primary carriers function for the pumping of a diverse range of substrates, 
including inorganic ions, vitamins, drugs, fatty acids and proteins (Saier, 2000).  Secondary 
transporters are responsible for the transport of most organic solutes across biological 
membranes (Saier, 2000).  Finally, group translocators phosphorylate substrates during 
transport (Paulsen et al., 2000).   
 Secondary transporters function by either symport, in which two or more molecular 
species are transported in the same direction across a membrane, or antiport, in which one or 
more molecular species are exchanged for one another across a membrane (Fig. 2.9) (Forrest et 
al., 2011; Saier, 2000).  Surprisingly, all forms of secondary active transport can be understood 
in terms of the alternating access mechanism (Fig. 2.9) (Forrest and Rudnick, 2009).  In this 
model, the substrate-binding site is alternately accessible to the cytoplasm and extracellular 
medium via an occluded state (Jardetzky, 1966; Padan et al., 2009). Jardetzky outlined three 
features of a transporter that operates via an alternating access mechanism: 1. The protein must 
contain a binding pocket in its interior, large enough to admit a small molecule; 2. The 
transporter must have the ability to assume two different conformations, such that the binding 
pocket is open to one side in one conformation and the opposite side in the other; and 3. The 
transporter must contain a binding site for the substrate in its binding pocket, the affinity of 
which is different in the two conformations (Fig. 2.9) (Jardetzky, 1966).  The conformational 
change itself can be very minor, in some cases a change of only a few angstroms in helices 
relative to each other is sufficient to determine whether the binding site is open or closed 
(Forrest and Rudnick, 2009; Jardetzky, 1966).  
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2.3. MdfA, a model for studies of MFS multidrug transporters 
MdfA is a 410 amino acid E. coli multidrug transporter from the Major Facilitator 
Superfamily that is composed of 12 TMH (Fig. 2.10) (Edgar and Bibi, 1997).  Cells 
overexpressing MdfA are resistant to a wide variety of structurally unrelated compounds 
including neutral, zwitterionic, and monovalent cations, such as chloramphenicol (Cml), 
ethidium bromide (EtBr), and TPP+ (Edgar and Bibi, 1997; Lewinson et al., 2006; 
Mazurkiewicz et al., 2005).  MdfA is restricted to a transport stoichiometry of one drug 
molecule per proton, and is essentially inactive toward divalent  
Figure 2.9.  Alternating access mechanism of substrate transport.  In each case, the substrate 
binding site is alternatively accessible to either side of the membrane via an occluded 
intermediate (top left).  Top right.  In uniport, a solute is transported from high to low solute 
concentration.  Middle and bottom, respectively.  In symport and antiport, the uphill 
transport of one solute is coupled to the downhill movement of another.  Symporters 
catalyze the transport of solutes in the same direction, and cannot transition from alternately 
facing conformations with only one substrate bound.  Antiporters catalyze the exchange of 
solutes from one side of the membrane to the other, and can only interconvert from one 
conformation to the other via a substrate bound form. Reproduced from Forrest and Rudnick 
(2009) with the permission of the publisher.   
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cations (Fluman and Bibi, 2009; Mazurkiewicz et al., 2005).  MdfA also has a low affinity Na+ 
(K+)/H+ antiport activity, and confers alkalitolerance up to pH 10, providing a potential answer 
to the debate over MdfA’s physiological role in E. coli (Lewinson et al., 2004).  Interestingly, 
MdfA is promiscuous not only in its substrate profile, but also in its use of components of the 
proton motive force, ΔpH and Δψ.  In cases where the substrate transported is neutral, MdfA 
catalyzes an electrogenic reaction, while in cases where the substrate is charged, the reaction is 
electroneutral (Lewinson et al., 2003).  The exact mechanism of substrate transport remains to 
be elucidated, and the understanding thereof has been hindered by the lack of three-dimensional 
structural information (Sigal et al., 2005).  However, the crystal structure of EmrD, a homolog 
of MdfA (26% identity and 39% similarity) was recently solved, and provides some insight into 
the binding pocket of MdfA (Yin et al., 2006).  
EmrD is a 394 amino acid E. coli multidrug transporter from the Major Facilitator 
Superfamily.  The EmrD structure was solved in the intermediate occluded state, in which the 
substrate-binding site is not accessible from either the cytoplasm or periplasm (Fig. 2.11).  The 
outer helices of EmrD are organized similarly to LacY and GlpT (Fig. 2.11) (Yin et al., 2006).  
Toward the interior of EmrD, computer simulations have shown that proline and glycine 
residues contribute to helix flexibility, a characteristic reminiscent of LacY and GlpT  
Figure 2.10. Secondary-structure model for MdfA based on the hydropathy profile and the 
distribution of positively charged residues (indicated in boldface type).  E26, D34, and 
V335 are indicated by red arrows.  Reproduced from Adler and Bibi (2002) with the 
permission of the publisher. 	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(Abramson et al., 2003; Baker et al., 2012; Huang et al., 2003).  The interior cavity, which is 
the presumed substrate-binding site, is large, flexible, and hydrophobic (Baker et al., 2012; Yin 
et al., 2006).  It contains several bulky and aromatic residues, uncharged polar residues, and a 
single basic residue, R118.  Yin and co-workers proposed that the hydrophobicity of the 
binding site may contribute to a general mechanism of substrate transport, and that steric and 
aromatic interactions are more directly related to drug specificity (Yin et al., 2006).  It is also 
thought that two pairs of stacked aromatic groups, Y52 and Y56, and W300 and F249, play key 
roles in multisubstrate binding.  The biochemistry of EmrD has not been well studied; as a 
result, it is challenging to draw further conclusions regarding substrate recognition and binding 
(Baker et al., 2012; Yin et al., 2006).  
Nevertheless, this data supports other studies indicating that MdfA has a large binding 
pocket, which is capable of binding multiple substrates simultaneously (Mazurkiewicz et al., 
2005; Sigal et al., 2005).  Evidence also suggests that MdfA is capable of binding hydrophobic 
substrates from the inner leaflet of the cytoplasmic membrane (Adler and Bibi, 2004; Krulwich 
et al., 2005).  In both EmrD and MdfA, charged residues on the cytoplasmic end of TMH-4 are 
involved in substrate recognition from the inner leaflet of the membrane (Adler and Bibi, 2004; 
Baker et al., 2012; Yin et al., 2006).  Transport of cationic drugs by MdfA appears to be 
dependent on E26, a membrane-embedded negatively charged residue in TMH-1 (Lewinson et 
Figure 2.11.  Ribbon representation of EmrD.  A. Side view of EmrD, with N- and C-
termini indicated.  B. Helical organization of EmrD as viewed parallel to the membrane.  
Reproduced from Yin et al. (2006) with the permission of the publisher. 	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al., 2006).  E26X mutants can have their cation-transport function restored by substituting a 
negatively-charged residue for V335 (Adler and Bibi, 2005).  Site-directed mutagenesis 
experiments showed that residues S321, Y323, R336, F340, R112, and D132 are also involved 
in substrate recognition; however, their exact functions remain unclear (Adler and Bibi, 2002; 
Adler and Bibi, 2005; Sigal et al., 2005).   
 
 
2.4. Characterization of membrane proteins 
2.4.1 Purification and functional reconstitution of transport membrane proteins 
Membrane protein structural and functional characterization is limited by the challenges 
associated with obtaining milligram quantities of pure, monodisperse membrane protein 
(Newby et al., 2009; Ostermeier and Michel, 1997). The generalized approach to 
overexpression and purification of a target membrane protein is overexpression of the target 
protein, followed by cell membrane isolation, membrane solubilization, and, finally, protein 
purification (Newby et al., 2009).   
Generally, bacterial membrane proteins can be successfully expressed in E. coli 
(Carpenter et al., 2008). Affinity tags are attached to the target protein by gene fusion, adding 
specific properties that can be used for protein purification via affinity chromatography 
(Arnold, 1991; Padan, 2003).  A frequent problem with membrane protein overexpression is 
misfolding and protein aggregation in the form of inclusion bodies.  Several tools exist to fight 
these challenges.  Cell growth and protein expression can be performed under reduced 
temperatures, or molecular chaperones can be used to assist in protein folding (Baneyx, 1999). 
Fine-tuning expression levels using promoters such as the ara promoter allows for the 
optimization of expression while minimizing protein aggregation (Guzman, 1995).   
Cells are harvested by centrifugation and lysed, generally, by mechanical disruption 
using a cell disrupter or sonicator.  Cell membranes are isolated by ultracentrifugation of the 
cell lysate (Newby et al., 2009).  Membrane proteins are then extracted from the cell membrane 
by the addition of detergents, amphipathic molecules comprising a polar head group and a 
hydrocarbon tail, which allow solubilization by covering the hydrophobic surfaces of the 
protein (Fig. 2.12) (Carpenter et al., 2008; Ward et al., 2001).  At the critical micelle 
concentration (CMC), detergent monomers aggregate, via hydrophobic effects, to form ordered 
structures into which membrane proteins can insert to create a protein-detergent complex 
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(PDC) (Ward et al., 2001; Wiener, 2004).  The CMC is characteristic of each detergent, but is 
also affected by the composition of the solvent (e.g. ionic strength) and temperature (Von 
Jagow et al., 2003; Wiener, 2004).  Detergents can be classified into three categories: ionic, 
which carry a net charge associated with their head group; non-ionic, which have uncharged 
hydrophilic head groups; and zwitterionic, which have both positive and negative charges but 
carry no net charge (Ward et al., 2001).  As a rule of thumb, the head group of a detergent tends 
to have a strong effect on the interaction of the detergent with the protein, while the length of 
the alkyl chain affects the detergent CMC, and aggregation number.  As a result, detergents 
with a larger head group and longer alkyl chain tend to be milder, and have lower CMCs.  An 
additional consideration is the charge on the head group, with neutral head groups being gentler 
detergents, and less likely to denature the protein (Privé, 2007).  Identifying the detergent most 
suitable for the purification of a particular protein target is an empirical process (Hunte, 2003; 
Newby et al., 2009).  One detergent may be optimal for solubilization and purification, whereas 
another may be best suited for structural studies (Hunte, 2003).  The ideal detergent extracts all 
the target protein from the membrane, maintains its native fold, and forms a PDC that is stable 
throughout purification and characterization (Newby et al., 2009; Ward et al., 2001).  Cell 
membranes are incubated with the detergent, and then ultracentrifuged to recover the 
solubilized material (Ward et al., 2001).   
This solution is then applied to an affinity chromatography column, and purified. These 
systems are designed to be highly specific and fast, allowing protein purifications with high- 
yield, and high-enrichment, often under mild-purification conditions.  The ideal tag should not 
affect the activity or structure of the protein of interest, or interfere with targeting, folding, or 
membrane insertion (Padan, 2003).  A variety of different affinity tags exist (eg. His-tag, Strep-
tag, Flag-tag, etc), but by far the most widely applied tag is the His6-tag (Padan, 2003; Ward et 
al., 2001).  This tag is small and should not decrease expression levels or have a deleterious 
effect on protein folding or membrane insertion (Ward et al., 2001).  Immobilized metal-
affinity chromatography beads, loaded with transition metal ions such as Ni2+, can be used to 
purify the tagged protein.  The protein of interest binds to the resin by interaction of the 
histidine imidazole groups with the free ligand binding sites in the coordination sphere of the 
metal ions, unbound protein is washed off, and the target protein can be eluted by adding free 
imidazole to the elution buffer or by altering the pH.  Nickel chromatography is also  
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successfully used for membrane protein purification (Newby et al., 2009; Padan, 2003).  This 
method allows 100-fold enrichments in a single purification step and up to 95% purity of the 
tagged protein.  Furthermore, the matrices tolerate the presence of detergents (Padan, 2003).  
Optimization of the column purification can be achieved by adjusting the number of imidazole 
wash steps, and the concentration of imidazole used (Newby et al., 2009).  In addition, since 
antibodies to the hexahistidine tag are commercially available, the purification steps can be 
easily monitored by Western blotting of the chromatography fractions and the resin to ensure 
that no protein is lost (Newby et al., 2009; Ward et al., 2001).  Additional purification using 
Figure 2.12. Structures of some detergents listed in Table 1 (Section 2.4.4), including 1-
myristoyl-2-hydroxy-sn-glycero-3-[phospho-rac -1-glycerol)] (LMPG) and 1,2-
diheptanoyl-sn-glycero-3-phosphocholine (DHPC). A. N-dodecyl-β-D-maltopyranoside 
(DDM).  B. LMPG.  C. N-octyl-β-D-glucopyranoside (OG). D. Dodecyloctaoxyethylene 
(C12E8). E. N,N-dimethyldodecylamine (LDAO). F. octyltetraoxyethylene (C8E4). G. 
DHPC.  
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size-exclusion chromatography and/or ion-exchange chromatography can be performed, but is 
not always necessary (Newby et al., 2009).   
In order to determine if a membrane transporter has been purified in its native, active 
form, functional reconstitution into an artificial lipid membrane is required (Geertsma et al., 
2008; Picard et al., 2012; Rigaud and Levy, 2003).  Four general physical and chemical 
techniques for the insertion of membrane proteins into liposomes exist: mechanical means (e.g. 
sonication), freeze-thawing, organic solvents, and detergents (Rigaud and Levy, 2003).  Of 
these, detergent-mediated protein reconstitution is the most successful and frequently used 
strategy, since most membrane proteins are isolated and purified using detergents.  
Reconstitution is achieved by first co-solubilizing the proteins and pre-formed liposomes in the 
appropriate detergent in order to form an isotropic solution of lipid-protein-detergent and lipid-
detergent micelles.  Detergent is then removed, resulting in the progressive formation of bilayer 
vesicles with incorporated protein.  The detergent can be removed by dialysis, adsorption onto 
polystyrene beads, gel chromatography, or dilution (Rigaud et al., 1995).  The focus of this 
discussion will be on protein reconstitution using either dialysis or hydrophobic resin 
techniques, as these are the two methods used in this project.   
Dialysis has been the most widely used method for detergent removal.  Briefly, the 
lipid-protein-detergent micellar solution is placed in a cellulose membrane bag with a cutoff of 
14 kDa, and dialyzed against a large volume of detergent-free buffer.  Only detergent 
monomers diffuse through the dialysis membrane.  Its main advantages are its simplicity, low 
cost, and the homogenous size dispersion of the resulting proteoliposomes.  However, this 
technique can also have some disadvantages, namely poor reproducibility, an uncontrolled rate 
of dialysis, possible molecule retention on the dialysis membrane, and the duration of the 
experiments (Rigaud and Levy, 2003).  Despite this, dialysis has been successful in the 
reconstitution of a variety of secondary transporters, including LacY and GlpT (Poolman and 
Konings, 1993).  
Detergents that cannot be readily removed by dialysis can be removed by hydrophobic 
adsorption onto polystyrene resins such as Bio-Beads SM-2 (BioRad) and Amberlite XAD 
(Sigma-Aldrich) (Rigaud and Levy, 2003).  In the batch procedure, Bio-Beads SM-2 are 
directly added to the protein-lipid-detergent mixtures, and replaced as needed (Rigaud and 
Levy, 2003; Venturi, 2003; Xie et al., 2004).  This method is predicted to be successful for the 
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removal of most detergents; however, its major limitation is the potential of lipid adsorption 
onto the beads (Rigaud and Levy, 2003).  
Detergent-mediated protein reconstitution into liposomes can yield proteoliposomes of 
varied number of lipid layers, size, and protein distribution, depending on the nature of the 
detergent, the particular detergent-removal procedure, the nature of the protein, and the lipid 
composition.  As a result, developing a reconstitution protocol is largely empirical (Rigaud and 
Levy, 2003).  In addition to selecting an appropriate detergent-removal technique, several other 
criteria must also be considered for optimization of the proteoliposomes in membrane protein 
studies: the integrity and activity of the reconstituted protein, the morphology and size of the 
proteoliposomes, the homogeneity of their size and protein distribution, the number of protein 
units incorporated, the final orientation of the incorporated protein, and the permeability of the 
proteoliposomes (Rigaud et al., 1995).  Optimal protein distribution is achieved by varying the 
protein:lipid ratios used for reconstitution, and protein incorporation efficiency is tested by a 
sucrose density gradient (Rigaud and Levy, 2003; Rigaud et al., 1995).  Unilamellar 
proteoliposomes of homogenous size are usually achieved by extrusion through a polycarbonate 
filter (Macdonald et al., 1991).   
 
2.4.2 Transport assays  
Initial characterization of transport proteins can be performed in crude cell membrane 
vesicles to determine the general substrate profile of a transporter, but for a more detailed 
analysis, a defined system with pure protein is required in which parameters can be varied 
systematically (Geertsma et al., 2008).  Transport of substrates or inhibition is studied in vitro 
using purified protein reconstituted into liposomes, as described in section 2.4.1 (Geertsma et 
al., 2008; Xie, 2008).  Most bacterial transport systems show good transport activity when 
reconstituted in lipid mixtures of 3:1 E. coli total lipids and egg phosphatidylcholine; however, 
E. coli total lipids alone have also been used successfully (Chao and Fu, 2004; Poolman et al., 
2005).   
Transport assays require substrate or an energy source to initiate transport, as well as a 
means of detecting substrate translocation across the membrane (Picard et al., 2012; Xie, 2008).  
Traditionally, isotopically-labeled substrates are used to measure substrate uptake into 
liposomes (Xie, 2008).  For example, to examine the kinetic mechanism of the lactose transport 
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system, LacS, of Streptococcus thermophilus, 14C- and 3H-labeled lactose and galactose were 
used as substrates.  The system was driven using the proton motive force: ΔpH was generated 
by using internal and external buffers with different pH values, while Δψ was generated using 
valinomycin, a potassium-selective ionophore.  The assay was started by the addition of the 
substrate, samples were withdrawn at selected time intervals, and then diluted and washed with 
buffer without substrate.  The amount of transported substrate was determined by liquid 
scintillation counting of the collected samples (Foucaud and Poolman, 1992).   
The basic assay described above can be modified as needed for a given transport 
system.  Another study, which also used radiolabeled substrates, investigated the transport 
mechanism of the vesicular glutamate transporter, VGLUT2 (Fig. 2.13).  Glutamate transport 
by VGLUT2 is driven by the membrane potential (positive inside).  As a result, the researchers 
co-reconstituted VGLUT2 and the bacterial FoF1-ATPase into preformed liposomes, and 
generated Δψ by proton transport into the liposome lumen upon the addition of ATP (Juge et 
al., 2006).  
On the other hand, radiolabeled substrates are not always readily available, and such 
experiments have distinct limitations.  To this end, it is often useful to test the transport reaction 
by using a fluorescent indicator that can indirectly probe transport, or to couple the substrate 
transport to an enzymatic reaction that can be detected spectroscopically (Heuberger and 
Poolman, 2000; Lewinson et al., 2003).  Heuberger and co-workers developed a coupled assay 
to test the putative xyloside-transporter, XylP, using a homologous, and well-characterized, 
transporter, LacS.  LacS-reconstituted liposomes were pre-loaded with pyrroloquinoline 
quinone-dependent aldose dehydrogenase.  Oxidation of sugars transported into the liposome 
by LacS would lead to the reduction of pyrroloquinoline quinone, followed by reoxidation by 
the artificial dye, 2,6-dicholorindophenol and phenazine methosulfate.  The reduction of 2,6-
dichlorindophenol can be followed spectrophotometrically at 600 nm with high sensitivity.  The 
authors of this study point out an advantage: as opposed to experiments with radioactive 
substrates, here the reactions can be followed in real-time, data sampling is continuous, and that 
high external substrate concentrations can also be used (Heuberger and Poolman, 2000).   
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Indeed, for members of the MFS, changes in pH or Δψ can be used as indirect indicators 
of substrate transport across a membrane.  Fluorescent probes such as 9-amino-6-chloro-2-
methoxyacridine (ACMA) or oxonol V, which are sensitive to ΔpH or Δψ, respectively, are 
especially useful in this regard.  As a proton gradient or electrical potential is generated, 
fluorescence is quenched.  Transport is observed by an increase in fluorescence upon the 
exchange of substrate for protons (Lewinson et al., 2003).  Indirect assays are especially 
important if the substrate profile of the transporter is not well characterized.   
 
2.4.3 Application of NMR spectroscopy to drug binding studies 
NMR can be used to obtain physical, chemical, and structural information about 
molecules.  The NMR spectra reflect the electronic environment of a nucleus, which produces a 
measureable change in nuclear resonance frequency characterized by the chemical shift 
(Nelson, 2003).  As a result, NMR spectroscopy can be used to monitor and measure the 
Figure 2.13.  Illustration of VGLUT2 activity assay.  VGLUT2 and FoF1 ATPase were co-
reconstituted into liposomes.  The addition of ATP (1) causes protons to be actively pumped 
into the liposome lumen by hydrolysis of ATP to ADP, creating a positive-inside membrane 
potential (2).  3H-Glutamate is transported into the liposome, and partially relieves the 
membrane potential (3).  At desired time points, the liposomes were separated from the assay 
mixture and the radioactivity of the buffer was measured in order to determine the amount of 
substrate transported (Juge et al., 2006). 
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interaction between ligands and proteins (Meyer and Peters, 2003; Xie, 2008).  Membrane 
proteins pose a variety of challenges for NMR-based ligand screening since they require a 
membrane-mimetic environment, such as detergent micelles, in order to maintain stability and 
function.  Detergents add to the molecular weight of the protein, increase the viscosity of the 
solution, overlap with protein signals, modulate protein dynamics and conformational 
exchange, as well as compromise sensitivity by adding highly intense background signals 
(Yanamala et al., 2010). While minimizing the size of the detergent micelle can improve NMR 
spectra, this is not always the case, and does not ensure a functional protein (Warschawski et 
al., 2011). 
 The reversible binding reaction, P + L = P*L, is characterized by the dissociation 
constant, Kd = [P][L]/[P*L], where P refers to free protein, L refers to free ligand, and P*L 
refers to the protein-ligand complex.  Kd is a measure of binding affinity.  Protein-ligand 
interactions can be observed by NMR by chemical shift and/or linewidth changes.  Either the 
protein or the ligand can be observed, as long as it is labeled with NMR-active isotopes such as 
13C and/or 15N (Meyer and Peters, 2003; Xie, 2008).   
Changes in linewidth indicate the overall relaxation time of the molecule; that is, as the 
relaxation time decreases, the linewidth broadens.  Relaxation times and the size of the 
molecule are directly related: larger molecules have shorter relaxation times (Doucleff, 2011).  
Therefore, free ligand has long relaxation times, and relatively narrow linewidth, while bound 
ligand has a shorter relaxation time, and broader linewidths.   
Ligand binding to the protein can result in changes in chemical shifts and relaxation 
parameters, which can be observed by NMR.  Chemical shift perturbations are either observed 
as the appearance of a separate peak corresponding to the protein-ligand complex (slow 
exchange), or a single peak that changes in chemical shift as more ligand or protein is titrated 
(fast exchange) (Zartler et al., 2003).  In other words, in slow exchange systems where the 
reporter group is on the ligand, separate peaks are observed for L and P*L.  Slow exchange 
indicates tight binding, and Kd cannot be calculated in this case (Evans, 1995).  However, for 
fast exchange, the observed chemical shift is the weighted average of the chemical shifts of the 
free and bound ligand states: both L and P*L are observed in one peak (Zartler et al., 2003).   In 
this case, Kd can be determined from the chemical shift changes.  For the reversible reaction 
P+L = P*L at equilibrium, the chemical shift of the reporter group in L is δL and the chemical 
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shift of the same reporter group in P*L is δP*L.  The observed chemical shift, δobs, will be a 
weighted average of the chemical shifts of P and P*L: δobs= δP x [P]/([P]+[P*L]) + δP*L x 
[P*L]/([P]+[P*L]).  The ligand binding constant, Kd, can then be determined from the chemical 
shift titration curve given that Kd =[P][L]/[P*L] and [L]+[P*L]=Ltotal, where Ltotal and δL are 
known (Evans, 1995).  In contrast to chemical shift perturbations, changes in relaxation times 
cannot be observed directly; as a result, slow and fast exchange models have to be fitted to the 
measured linewidths, which can complicate the extraction of binding parameters (Meyer and 
Peters, 2003; Xie, 2008).  In order to accurately distinguish between the affinity of ligand for 
protein, and binding site saturation, it is critical to use excess ligand for these studies (Zartler et 
al., 2003).  When observing ligand signals, it is important to distinguish whether signal changes 
are caused by ligand-detergent interactions or ligand-protein interactions; a reference spectrum 
is thus required (Yanamala et al., 2010).  
  Signal overlap in binding studies can be significantly reduced by using heteronuclear 
single quantum coherence (HSQC) experiments (Meyer and Peters, 2003; Yanamala et al., 
2010).  This is especially powerful for ligand screening and kinetic studies, where chemical 
shift perturbations of 15N-labeled protein in 1H,15N-HSQC experiments can be more easily 
observed than one-dimensional proton spectra (Meyer and Peters, 2003; Shuker et al., 1996).  
On the other hand, known ligands can also be labeled with NMR-active isotopes such as 15N 
and 13C and isotope-edited 1H-NMR experiments can be used to detect ligand-protein 
interactions. The resulting spectra are one-dimensional proton spectra that correspond to the 
isotope used (Derrick et al., 1992).  Chemical shift perturbations or linewidth broadening 
corresponding to protein binding of ligand is detected as with any other NMR experiment 
(Derrick et al., 1992; Zartler et al., 2003).    
 NMR can also be used for tertiary structure determination of proteins, but it has serious 
limitations that hinder its widespread application to the structural biology of membrane 
proteins.  For multidimensional NMR experiments, samples must be labeled with NMR-
sensitive isotopes, such as 13C and 15N.  Labeling protein samples occurs during protein 
expression, and if the protein yield is low, as it generally is with membrane proteins, isotope 
labeling can be prohibitively expensive (Fernandez and Wuthrich, 2003).  Cell-free synthesis of 
the protein of interest can lower costs, but is not a widely used technique (Basting et al., 2006).  
As with any studies of membrane proteins, selection of a detergent, which simultaneously 
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maintains native structure and function and yields high quality NMR spectra, is largely a trial 
and error process.  In addition, some proteins can bind up to twice their weight in detergent, 
adding to their size.  Since large molecules tumble more slowly in solution, the resulting spectra 
are often poorly resolved and not amenable to structure determination studies (Sanders and 
Sonnichsen, 2006).  For helical membrane proteins, three main challenges exist: 1. Low 
spectral dispersion that impedes resonance assignments; 2. A limited set of long-range distance 
constraints; and 3. Unstable tertiary folds that can enlarge linewidth (Lacapere et al., 2007; 
Sanders and Sonnichsen, 2006).  Particular solution NMR techniques such as transverse 
relaxation-optimized spectroscopy can yield more useful spectra, and have applications to 
proteins ranging in size from 50-900 kDa (Fernandez and Wuthrich, 2003).  Unfortunately, 
solid state NMR, particularly useful for beta-barrel membrane proteins, is presently limited to 
single or double spanning transmembrane proteins due to low spectral dispersion (Basting et 
al., 2006; Lacapere et al., 2007).  As a result, though it is extremely difficult to obtain high 
quality crystals of membrane proteins, X-ray crystallography remains the method of choice for 
high resolution structure determination of helical membrane proteins, and especially of MFS 
type transporters (Lacapere et al., 2007; Sanders and Sonnichsen, 2006).   
 
2.4.4 Membrane protein crystallography 
Tertiary structure of proteins can be visualized by X-ray crystallography.  Briefly, 
protein crystallography entails growing high-quality crystals of purified protein, and measuring 
the directions and intensities of X-ray beams diffracted from the crystals (Lattman and Loll, 
2008; Rhodes, 2000).  The resulting diffraction pattern is collected, and a three-dimensional 
structure is calculated and refined using computer analysis (Lattman and Loll, 2008).   
Finding optimal conditions for crystal growth largely involves trial and error.  Protein 
crystals are grown by slow, controlled precipitation from aqueous solution.  Crystal formation 
is affected by variables such as protein purity, concentrations of protein and precipitant, pH, 
and temperature.  Moreover, the crystallized protein must retain its biological function in its 
crystallized form; an essential part of any structure determination project is an effort to show 
that the crystallized protein is not significantly altered.  Membrane protein crystallography 
extends this challenge further by adding yet another dimension: hydrophobicity (Carpenter et 
al., 2008).  Hydrophobicity alone can account for the fact that while membrane proteins 
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represent a third of proteins encoded in most genomes, but only about 360 proteins of known 
structure to date (as compared to approximately 85,000 protein structures overall) 
(http://blanco.biomol.uci.edu/mpstruc/listAll/list, accessed 10 September 2012; 
http://www.pdb.org/pdb/home/home.do, accessed 10 September 2012; Carpenter et al., 2008; 
Loll, 2003).   
Of course, most membrane proteins are crystallized in the presence of a solubilizing 
agent, such as a detergent, and detergent selection is a major limiting step in membrane protein 
crystallography (Lemieux et al., 2003; Ostermeier and Michel, 1997).  In general, the PDC is 
not very amenable to X-ray crystallography or NMR studies.  Successfully obtaining a crystal is 
difficult because the flexible and dynamic nature of the detergent belt that surrounds the protein 
does not favor the formation of well-ordered lattices (Privé, 2007).  Detergents are prone to 
partition out of aqueous solution at high precipitant concentrations, introducing a detergent-rich 
phase in the crystallization drop (Newby et al., 2009).  In addition, while attractive interactions 
between the detergent micelles may stabilize the crystal packing, detergent molecules require 
space in the crystal lattice, and these interactions do not lead to rigid crystal contacts (Hunte 
and Michel, 2002). The detergent micelle has to fit optimally into the crystal lattice (Ostermeier 
and Michel, 1997).  Finding the optimal micelle size can be done by experimentation with 
longer or shorter homologs of the original detergent. 
In practice, a variety of detergents should be tested for their ability to maintain the 
solubility and stability of the protein of interest (Iwata, 2003; Ostermeier and Michel, 1997).  
Typically, a detergent concentration of 2-3 times the CMC is used.  Suitable detergents can then 
be used in protein crystal trials, and once crystals are obtained, further optimization of the 
detergent can be performed to get high-quality crystals (Iwata, 2003).  A first set of alternative 
detergents to those used in protein purification can be selected on the basis of past success 
stories.  Table 1 lists the most widely used detergents in X-ray crystallography studies of 
membrane proteins, based on statistics from the Membrane Protein Data Bank 
(http://www.lipidat.chemistry.ohio-state.edu/MPDB/index.asp, accessed May 2012). 
Detergent-protein suspensions have to be screened to ensure that the protein is 
monodisperse, since proteins that aggregate in solution generally are not suitable for high 
resolution structure determination (Engel et al., 2002; Lemieux et al., 2003; Rhodes, 2000; 
Roth et al., 1989).  Protein aggregation is also greatly influenced by pH: most proteins 
	   35	  
crystallize over a pH range of 4-9 (Lemieux et al., 2003).  For those proteins that are unstable in 
detergent micelles, lipidic cubic phases have been found to be a possible alternative (Landau 
and Rosenbusch, 1996; Ostermeier and Michel, 1997).  A lipid cubic phase is a quasisolid 
three-dimensional membrane array that is pervaded by an intercommunicating aqueous channel 
 
Table 1. Detergents used in successful X-ray structural studies of membrane proteins, in 
order of number of reported structures (Raman et al., 2006). 
Detergent Number of reported structures CMC (mM) 
OG 79 20 
DDM 52 0.16 
C8E4 43 7 
LDAO 22 1 
CHAPSO 18 10 
C12E8 18 0.08 
Triton-X 100 16 0.24  
 
system (Fig. 2.14).  These matrices provide nucleation sites that can grow by lateral diffusion of 
membrane protein molecules (Fig. 2.14) (Landau and Rosenbusch, 1996).   
In a sense, following the selection of an appropriate detergent, and the determination of 
the pH and salt concentration at which the protein remains monodisperse, crystallization and 
crystal analysis of membrane proteins is no different than that of soluble proteins (Ostermeier 
and Michel, 1997).  However, the selection of precipitants that can be used is significantly less 
than those possible for soluble proteins.  Organic solvents tend to disturb detergent micelles 
and, at high concentrations, can even denature proteins.  Salts, on the other hand, reduce the 
solubility of detergent micelles and precipitate the membrane protein embedded in the detergent 
micelle before crystallization occurs.  It is not surprising that, by one count, over 75% of 
membrane protein crystals have been grown using polyethylene glycols (PEG) or their 
monomethyl ether derivatives (Lemieux et al., 2003).  However, even after the careful selection 
of detergent, pH value, and precipitant, crystals suitable for detailed structural analysis may not 
form.  Lemieux et al., in their attempts to crystallize GlpT, found that soaking crystals in heavy 
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metal salts such as PbCl2 improved crystal order by a factor of 1.5-2.4, depending on the salt 
added (Lemieux et al., 2003).  
Secondary transporters, in particular, are a class of membrane proteins that are 
especially difficult to crystallize as their small extramembranous surface areas make them 
extremely hydrophobic, and they exhibit a high degree of internal flexibility (Carpenter et al., 
2008; Engel et al., 2002).  In order to extend the surface area of the soluble portion of the 
membrane protein and enhance crystal contacts, the protein of interest can be co-crystallized 
with the Fv fragment of a monoclonal antibody (Ostermeier et al., 1995; Ostermeier and 
Michel).  Antibody fragments are well suited for use in co-crystallization with membrane 
proteins because they are readily available and have both high affinity and specificity.  Fv 
fragments are optimal, as Fab fragments show internal flexibility and may not enhance crystal 
contacts.  In addition, the former can be efficiently produced in E. coli, purified by affinity 
chromatography, and often easily crystallized (Ostermeier et al., 1995).  An Fv fragment should 
be selected which extends out of the detergent micelle when bound, and which selectively binds 
the native protein (Hunte and Michel, 2002; Ostermeier et al., 1995).  This method has been 
Figure 2.14.  Schematic model of a bicontinuous cubic phase composed of monoolein, water, 
and a membrane protein. The matrix consists of two compartments, a membrane system with 
an infinite three- dimensional periodic minimal surface (Left), interpenetrated by a system of 
continuous aqueous channels (shown in black). The enlarged section (Right) shows the curved 
lipid bilayer (with an inserted membrane protein molecule) enveloping a water conduit.  
Lateral diffusion of membrane proteins through the lipid bilayer allows for crystal nucleation 
and growth to occur.  Reproduced from Landau and Rosenbusch (1996), with the permission 
of the publisher.   
 
	   37	  
used successfully to solve the structures of membrane proteins such as cytochrome c oxidase 
from Paracoccus denitrificans, cytochrome bc1 complex, and the potassium channel (Hunte and 
Michel, 2002; Knol et al., 1996).   
 The solution structure of LacY demonstrated that the internal flexibility of a molecule 
must be considered, and if necessary, strategies to overcome it must be devised.  Since LacY is 
known to be a very dynamic molecule, Abramson and coworkers tested a variety of LacY 
mutants for conformational flexibility, and selected C154G, a particularly stable, 
conformationally-arrested mutant, for crystal trials (Abramson et al., 2003; Smirnova and 
Kaback, 2003).  C154G LacY had the added benefit of being able to bind a substrate analog, 
which not only confirmed that the binding site of LacY was intact, but also allowed valuable 
insight into the binding site of MFS transporters (Abramson et al., 2003).   
  
2.5 Implications for studies of putative bacterial multidrug transporters  
MdfA is a model MDT from the MFS family.  Since membrane proteins are extremely 
challenging to study, developing well-characterized models is a more efficient approach to 
tackling the question of active drug extrusion from the cell.  MFS multidrug transporters are 
significant players in S. aureus multidrug resistance (Li and Nikaido, 2009).  However, many of 
these transporters remain uncharacterized.  Gaining a more detailed understanding of the 
structure, mechanism and substrate profile of known transporters such as MdfA will not only 
allow for the development of techniques by which to study putative drug transporters, but will 
also lead to the development of novel strategies to combat efflux mediated drug resistance in 
virulent pathogens such as MRSA.   
The aim of this project was to develop techniques for the structural and functional 
characterization of putative MDT using MdfA as a model.  MdfA can be used to develop 
substrate profile assays that are universally applicable to transporters energized by a proton 
gradient.  Once the substrate profile of a transporter has been determined, the kinetics of 
substrate binding can be determined.  We sought to develop a substrate profile assay by 
measuring ACMA fluorescence changes associated with substrate transport in MdfA-
reconstituted proteoliposomes.  Next, we tested whether NMR isotope-editing techniques can 
be used to determine the dissociation constant of substrate binding to pure MdfA in detergent 
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micelles.  Finally, we sought to perform crystal trials of MdfA to identify conditions suitable 
for structural studies using X-ray crystallography.   
3. Experimental Procedures1 
3.1. MdfA expression and purification 
3.1.1 Expression of MdfA in E. coli  
 
MdfA was expressed as described previously (O'Grady, 2010).  Briefly, E. coli strain 
LMG194/pCOG3 was plated onto a Luria-Bertani (LB) media (170 mM NaCl, 10 g/L tryptone, 
5 g/L yeast extract) agar plate containing 100 µg/mL ampicillin and was incubated overnight at 
37 °C.  The starter culture was made by inoculating a single colony from the plate into 120 mL 
LB media with 100 µg/mL ampicillin.  Large-scale growth was performed by inoculating either 
6 or 12 L of LB media, containing 100 µg/mL ampicillin, with the starter culture (1:100 v/v), 
and growing the cells at 37 °C on a shaker platform at 200 r.p.m. to an optical density (OD600) 
of 0.5.  The cells were harvested and resuspended in casamino acid medium containing 2% 
casamino acids, 0.5% glycerol, 1 mM MgCl2, 42 mM Na2HPO4, 22 mM KH2PO4, 9 mM NaCl, 
and 100 µg/mL ampicillin.  MdfA expression was induced using 0.002% L-arabinose for 4 
hours.   
 
3.1.2 Preparation of E. coli cell membranes  
 
Membranes were purified as described previously (O'Grady, 2010).  Cells were 
harvested by centrifugation at 6000 x g, and then lysed using a Constant Systems Ltd 
(Daventry, Northants, U.K.) cell disruptor at 35,000 p.s.i. in TMDG buffer (50 mM Tris-HCl, 
pH 7.5, 5 mM MgCl2, 10% (v/v) glycerol, 1 mM dithiothreitol (DTT), and 1 mM 
phenylmethylsulfonyl fluoride (PMSF)).  Cell debris was removed by centrifugation (7,700 x g 
for 15 min at 4 °C), and the supernatant was centrifuged at 100,000 x g for 75 min at 4 °C to 
isolate the membranes.  The membrane pellet was resuspended in TMDG buffer and 
centrifuged again under the same conditions.  The pellet was then resuspended again in TMDG 
buffer, frozen in liquid nitrogen, and stored at -80 °C until use.   	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  1	  Chemicals used in these experiments were purchased from Sigma-Aldrich (Oakville, Ontario), Fisher Scientific 
Company (Ottawa, Ontario), or Merck Canada Inc., (Kirkland, Quebec) unless otherwise stated.   
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3.1.3 MdfA purification by Ni2+- affinity chromatography  
A purification procedure for MdfA from E. coli cell membranes has been developed in 
our lab (O'Grady, 2010).  MdfA was extracted by diluting the membranes to 10 mg protein/mL 
with TMDG buffer containing 2% (w/v) DHPC (Avanti Polar Lipids, Inc., Alabaster, Alabama) 
or DDM (Anatrace Detergents and Lipids, Maumee, Ohio).  The sample was gently agitated for 
30 min at 4 °C, and then centrifuged at 220,000 x g for 1 hour to separate soluble and insoluble 
protein.  The supernatant was diluted 1:5 (v/v) in TMDG buffer, and centrifuged again under 
the same conditions.  The supernatant was applied to a column containing nickel nitrilotriacetic 
acid agarose (Ni-NTA), pre-washed with TMDG buffer containing 0.2% (w/v) DHPC, at a ratio 
of 5:1 (v/v) membrane extract to Ni-NTA (Qiagen Inc., Toronto, Ontario).  Purifications were 
performed with either TMDG or KPi (50 mM KH2PO4, pH 7.5, 1 mM DTT) as buffer with 
additions as indicated below.  Contaminating proteins were washed off with 20 column 
volumes of 0.4% (w/v) DHPC and 20 mM imidazole (Merck Canada Inc.).  Detergent exchange 
was performed by washing the column with 10 column volumes of the detergent of interest at 
the desired concentration in the presence of 20 mM imidazole, followed by elution.  MdfA was 
eluted from the column using 5 column volumes 250 mM imidazole and 0.2% (w/v) LMPG, 
0.4% (w/v) DDM or 0.4% (w/v) DHPC.  For crystallization trials, MdfA was exchanged into 
OG, DDM, C12E8, and LDAO by Ni-NTA chromatography.  The final detergent concentrations 
used were 1.75% (w/v) OG, 0.4% (w/v) DDM, 0.013% (w/v) C12E8, and 0.07% (w/v) LDAO.  
Samples from each purification step were analyzed by sodium dodecylsulfate polyacrylamide 
gel electrophoresis (SDS-PAGE) (see section 3.7.4).   
To improve the purity of the MdfA sample, an imidazole gradient elution from a nickel 
affinity column was used.  A membrane sample was prepared and solubilized as described 
above using an ÄKTA FPLC system  (GE Healthcare, Mississauga, Ontario) at a flow rate of 1 
mL/min.  The solubilized membrane sample was loaded onto a Qiagen Ni-NTA superflow 
column, and the column was washed with TMDG buffer containing 20 mM imidazole and 
0.005 or 0.01% LMPG.  A linear gradient of imidazole concentration 20-500 mM was applied, 
and the column was further washed with 500 mM imidazole and 0.005% or 0.01% LMPG.  To 
further improve purity and to reduce nonspecific binding to the column, chromatography was 
performed as before, except that 0.5 M NaCl was added to the washes and elution buffers.   
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As a final step, buffer exchange was performed using a 10,000 molecular weight cutoff 
membrane concentrator by successive cycles of dilution and concentration of the protein in the 
desired buffers. Routinely, MdfA was concentrated to 5-11 mg/mL in 25 mM sodium 
phosphate, pH 6.0, 50 mM NaCl and 0.2% LMPG, or 0.4% DDM.    
 
3.2. FoF1 ATPase expression and purification 
3.2.1 Expression of FoF1 ATPase in E. coli  
 
E. coli strain C43(DE3) containing pBWU13, a plasmid that encodes the E. coli atp 
operon with the atpB gene modified to include a hexahistidine tag at the N-terminus of subunit 
a, was used for  FoF1 ATPase expression (Pierson et al., 2011; Stalz et al., 2003).  Cell culture 
was plated onto an LB agar plate containing 100 µg/mL ampicillin and was incubated overnight 
at 37 °C. The starter culture was made by inoculating a single colony from the plate into 30 mL 
LB containing 100 µg/mL ampicillin.  Large scale growth was performed by inoculating 6 L 
minimal media (15 mM NH4Cl, 15 mM Na2SO4, 0.8 mM MgSO4, 100 mM potassium 
phosphate, pH 7.0 (VWR International, Mississauga, Ontario) 0.05 µg/L FeSO4, 0.3% glucose 
and 5 mg/L thiamine) containing 100 µg/mL ampicillin, with the starter culture (1:250 v/v), and 
growing the cells to an OD600 of 1.6 at 37 °C on a shaker platform at 200 r.p.m.  The cells were 
harvested and membranes were prepared as described in section 3.1.2.  
 
3.2.2 Detergent screening for FoF1 ATPase purification 
The stability of FoF1 ATPase in different detergents was determined by testing ATPase 
activity using the malachite green assay (see section 3.7.1).  E. coli cell membranes were 
prepared as described in section 3.1.2.  An aliquot of E. coli membranes was pelleted by 
centrifugation at 220,000 x g for 20 min, and resuspended in 50 mM 3-(N-
morpholino)propanesulfonic acid (MOPS)-KOH, pH 7.0.  Membrane solubilization by Triton-
X 100 was optimized by varying protein concentration (2.5, 5.0 or 10.0 mg/mL) and detergent 
concentration (0.5, 1.0, 1.5, 2.0, 2.5, or 3.0% (w/v)).   Further screening was performed by 
preparing membrane extracts solubilized at 5.0 mg/mL protein concentration using 2.0% (w/v) 
Triton-X 100, or 2.0% (w/v) OG, or 1.0% or 0.2% (w/v) DHPC.  The membrane-detergent 
suspension was agitated gently for 30 min, and centrifuged at 200,000 x g for another 30 min to 
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remove insoluble protein.  The membrane extracts were tested for ATPase activity and N,N'-
dicyclohexylcarbodiimide (DCCD) sensitivity as described in section 3.7.1.    
 
3.2.3 Optimization of FoF1 ATPase purification by polyethylene glycol fractionation 
FoF1 ATPase purification was based on Propionigenium modestum (P. modestum) FoF1 
ATPase purification (Laubinger and Dimroth, 1988).  All centrifugation steps were performed 
at 4 °C.  An aliquot of E. coli membranes was pelleted by centrifugation at 220,000 x g for 20 
min, and resuspended in 50 mM MOPS-KOH, pH 7.0.  Membranes were solubilized at 5.0 
mg/mL protein concentration using 2.0% (w/v) Triton-X 100.  The membrane detergent 
suspension was agitated gently for 30 min, and centrifuged at 200,000 x g for another 30 min to 
remove insoluble protein.  MgCl2 was added to a final concentration of 50 mM, and the sample 
was divided in equal parts and treated with various concentrations of polyethylene glycol (PEG) 
6000 (Alfa Aesar, Ward Hill, Massachusetts) while stirring.  The final PEG 6000 
concentrations tested were 0, 2, 4, 6, 8, 10, or 12%.  These mixtures were centrifuged at 39,000 
x g for 20 min.  The pellet was resuspended in either buffer A (5 mM potassium phosphate, pH 
7.0, containing 1 mM DTT, 1 mM PMSF and 0.05% Triton-X 100), or in buffer B (10 mM 
Tris-HCl, pH 8.0, containing 5 mM MgCl2, 1 mM DTT, 1 mM PMSF, and 0.05% Triton-X 
100).  Insoluble material was removed by centrifugation at 39,000 x g for 15 min.  The FoF1 
ATPase was stored under liquid nitrogen until use.   
 Analysis of the purification steps was done by SDS-PAGE (see section 3.7.4).  In some 
cases, Western blot analysis was also performed to test for the presence of the His-tagged 
subunit a, or for subunit c of the FoF1 ATPase complex (see section 3.7.4). 
 
3.2.4 Ni2+-affinity chromatography of FoF1 ATPase with imidazole gradient elution 
The FoF1 ATPase was further purified by Ni-NTA column chromatography using the 
hexa-His tag attached to subunit a.  The following steps were performed using an ÄKTA 
FPLC system (GE Healthcare), at a flow rate of 1 mL/min.  The FoF1 ATPase sample was 
prepared by membrane solubilization using 2.0% (w/v) Triton-X 100, and PEG fractionation 
using 2.0% and 10.0% PEG 6000.  This sample was then loaded onto a Ni-NTA superflow 
(Qiagen) column.  The column was washed with buffer A, a linear gradient of imidazole 
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concentration 0-200 mM was applied, and the column was further washed with 200 mM 
imidazole.  Fractions collected were analyzed by SDS-PAGE (see section 3.7.4). 
 
3.3 Preparation of preformed liposomes and Bio-Beads 
Preformed liposomes and Bio-Beads were prepared essentially as previously described 
(O'Grady, 2010).  Lipid from an E. coli total lipid (Avanti Polar Lipids) extract in chloroform 
was dried under a gentle stream of argon, to remove the organic solvent, and resuspended in 25 
mM potassium phosphate buffer, pH 7.0, 2 mM β-mercaptoethanol, and 1.5% OG to a final 
lipid concentration of 25 mg/mL.  Liposomes were dialyzed against 25 mM potassium 
phosphate buffer, pH 7.0, and 2 mM β-mercaptoethanol using 12,000-14,000 MWCO 
Spectra/Por dialysis tubing to remove the detergent.  Liposomes were stored under liquid 
nitrogen until use.   
Bio-Beads SM-2 (BioRad Laboratories Ltd., Mississauga, Ontario) were prepared by 
addition to 100% methanol at a 1:7 ratio (w/v).  The slurry was mixed for 15 min, then 
transferred to a column, and washed with 200 mL methanol, followed by 700 mL ddH2O.  The 
Bio-Beads were then degassed for three hours, washing with ddH2O every hour.  Bio-Beads 
were stored under water at 4 °C until use. 
 
3.4. Reconstitution of MdfA and FoF1 ATPase in proteoliposomes 
3.4.1 Reconstitution using Bio-Beads 
MdfA was reconstituted into proteoliposomes by detergent disruption of preformed 
liposomes (see section 3.3), followed by detergent removal by Bio-Beads as described 
previously (O'Grady, 2010).  Preformed liposomes were thawed and passed through a mini-
extruder (Avanti Polar Lipids) using a Whatman 400-nm polycarbonate membrane filter (GE 
Healthcare) 20 times.  Note that for all proteoliposomes reconstituted using Bio-Beads, MdfA 
in 0.005% LMPG was used.  To each liposome sample, 30 µg MdfA was added, followed by 
either 2% (w/v) Triton-X 100 or 1% (w/w) DHPC.  Samples were incubated at 30 °C for 15 
min.  Bio-Bead treatment was performed by sequentially adding 10, 10, 20, 20 and 60 mg of 
Bio-Beads to the 300 µL sample and incubating for 30 min at 30 °C after each addition.  The 
Bio-Beads were then removed, and the proteoliposomes were stored on ice until use.  Control 
liposomes were treated and prepared in the same way, without the addition of MdfA.  
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The FoF1 ATPase was reconstituted into proteoliposomes by detergent disruption of 
preformed liposomes, followed by detergent removal by Bio-Beads, similar to the procedure 
described above.  Preformed liposomes were thawed, and 1% (w/w) DHPC was added to each 
liposome sample, followed by FoF1 ATPase at the desired protein:lipid ratio (w/w).  Samples 
were then treated with Bio-Beads as described above.  The Bio-Beads were removed, and 
samples were centrifuged at 220,000 x g for 20 min.  The supernatant was discarded and the 
proteoliposomes were resuspended in quench buffer A (20 mM Tricine-NaOH, pH 8.0, 10 mM 
MgCl2, and 300 mM KCl) in a volume equal to the starting liposome volume.  The suspension 
was passed through a Whatman 400-nm polycarbonate membrane 20 times, and the 
proteoliposomes were stored on ice until use. Control liposomes were treated and prepared in 
the same way, without the addition of protein.   
MdfA and FoF1 ATPase co-reconstitution was achieved in the same way, with the 
exception that in co-reconstitution experiments, the MdfA:lipid ratio was altered, while the FoF1 
ATPase:lipid ratio was constant.  Control liposomes were treated and prepared in the same way; 
however, MdfA was not added. 
 
3.4.2 Reconstitution using dialysis and freeze/thaw cycles 
 
For co-reconstitution of MdfA and FoF1 ATPase by dialysis, MdfA in 0.4% DHPC was 
concentrated to 5-11 mg/mL in KPi buffer, and protein concentration was determined by 
densitometry (see section 3.7.4).   MdfA and FoF1 ATPase co-reconstitution by dialysis was 
achieved by DHPC disruption of preformed liposomes, followed by detergent removal by 
dialysis.  Initial experiments were performed with the FoF1 ATPase alone.  Preformed 
liposomes were thawed, and 5 mM MgCl2 and 1% (w/w) DHPC was added to each liposome 
sample, followed by FoF1 ATPase at the desired protein:lipid ratio (w/w).  Samples were 
incubated at 30 °C and 400 r.p.m. for 30 min.  The samples were then dialyzed against dialysis 
buffer B (20 mM Tricine-NaOH, pH 8.0, 5 mM MgCl2, 200 mM KCl, 1 mM DTT), dialysis 
buffer C (5 mM Tricine-NaOH, pH 8.0, 5 mM MgCl2, 200 mM KCl, 1 mM DTT), dialysis 
buffer D (1 mM Tricine-NaOH, pH 8.0, 5 mM MgCl2, 200 mM KCl, 1 mM DTT), or dialysis 
buffer E (20 mM Bis-Tris propane-MES (EMD Inc., Mississauga, Ontario), pH 8.0, 5 mM 
MgCl2, 1 mM DTT) twice over 20 hours using 12,000-14,000 MWCO Spectra/Por (VWR 
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International) dialysis tubing at 4 °C.  Proteoliposomes were collected, incubated at 25 °C for 
10 min and submitted to three freeze/thaw cycles in liquid nitrogen.  
MdfA and FoF1 ATPase co-reconstitution was achieved in the same way, with the 
exception that in co-reconstitution experiments, the MdfA:lipid ratio was altered, while the FoF1 
ATPase:lipid ratio was constant.  Control liposomes were treated and prepared in the same way, 
without the addition of MdfA.   
This procedure was optimized by first reconstituting each protein individually using the 
dialysis method described above.  The FoF1 ATPase:lipid ratio used was 1:80, and the 
MdfA:lipid ratio was 1:40.  Following dialysis, the mono-reconstituted liposomes were mixed 
at the desired ratio, incubated at 25 °C, and submitted to three freeze/thaw cycles in liquid 
nitrogen.   
All liposomes suspensions were passed through a Whatman 400-nm polycarbonate 
membrane 20 times, and the proteoliposomes were stored on ice until use.  Control liposomes 
were always treated and prepared in the same way, without the addition of MdfA. 
 
3.4.3 Fractionation of proteoliposomes by ultracentrifugation in sucrose density gradient 
 Co-reconstitution of MdfA and FoF1 ATPase was confirmed by density fractionation.  
Sucrose solutions were prepared in quench buffer B (20 mM Tricine-KOH, pH 8.0, 5 mM 
MgCl2, 300 mM KCl, 1 mM DTT).  Proteoliposomes were layered over a 10-45% (w/w) 
sucrose density gradient and ultracentrifuged in a swing-out rotor at 150,000 x g for 16 hours at 
4 °C.  Fractions collected were analyzed by silver stained SDS-PAGE gels, Western blot (see 
section 3.7.4) and turbidity measurements at OD600.   
 
3.5. NMR experiments for measurement of substrate binding to MdfA 
3.5.1 Synthesis of 13C-labeled and natural isotopic abundance acetyl chloramphenicol  
13C-labeled and natural isotopic abundance acetyl chloramphenicol (13C-AcCml and 
AcCml, respectively) were synthesized by acetylation of chloramphenicol with 13C-acetyl 
chloride or natural isotopic abundance acetyl chloride as described previously (Derrick et al., 
1991).  Mono- and di-acetylated products were separated as follows.  The crude reaction 
product was dissolved in dichloromethane, and loaded onto a silica column.  A 0-30% (v/v) 
ethyl acetate:hexane gradient was used to separate mono- and di-acetylated Cml.  Separation 
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was confirmed by thin layer chromatography with 50% (v/v) ethyl acetate:hexane as a mobile 
phase.  Plates were viewed using shortwave ultraviolet light.  Each product was dried in a rotor 
evaporator, and redissolved in deuterated acetonitrile (Cambridge Laboratories Isotopes, Inc., 
Andover, Massachusetts).  
All 1H,13C-HSQC experiments were performed on a 600 MHz Avance NMR 
spectrometer (Bruker) at 27 °C.  NMR spectra were processed and analyzed using Felix-2000 
(Accelrys).   
 
3.5.2 Determination of  [13C ]-acetyl chloramphenicol concentration  by NMR 
The concentration of 13C- AcCml was determined using a 13C-acetyl-15N-glycine (NAG) 
(Cambridge Laboratories Isotopes, Inc.) standard.  NAG and 13AcCml solutions were made in 
NMR buffer (25 mM Na2HPO4, pH 6.0, 50 mM NaCl, 0.5 mM 4,4-dimethyl-4-silapentane-1-
sulfonic acid (DSS), 5% D2O (Cambridge Laboratories Isotopes, Inc.), and 0.005% (w/v) 
LMPG).  One-dimensional 1H,13C-HSQC  spectra were recorded using 1024 scans.  A standard 
curve was made by measuring signal intensity of the methyl group of NAG as a function of 
NAG concentration.  The 13C- AcCml concentration was determined by comparing the signal 
intensity of the methyl group of 13C- AcCml to the standard curve.    
 
3.5.3 Measurement of [13C ]-acetyl chloramphenicol binding to MdfA by one-dimensional 
1H,13C-heteronuclear single quantum coherence experiments   
MdfA was titrated in NMR buffer containing 20 µM 13C- AcCml to 4, 8, 12, 16, or 20 
µM.  A one-dimensional 1H,13C-HSQC spectrum of each sample was recorded using 1024 
scans.  This same set of experiments was repeated in the presence of 1.5 mM Cml.  To control 
for nonspecific binding of LMPG to 13C- AcCml, the titration experiment was repeated by 
titrating 0.005% (w/v) LMPG to the substrate solution, in the absence of MdfA.   
 
3.6 Development of crystallization conditions for structural studies of MdfA 
Prior to this project in our lab, initial crystallization screens were performed (O'Grady, 
2010).  These studies were used to select crystallization conditions for further optimization 
(Table 2).  Trials with the MemSys kit (Molecular Dimensions) were also performed as listed in 
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Table 2.  Phosphate buffer was composed of 25 mM Na2HPO4, pH 6.0, 50 mM NaCl.  All trials 
were checked at days 1 and 3 and weekly thereafter.  A 5.2 mg/mL MdfA sample in phosphate 
buffer was also sent for high-throughput screening at the Hauptman-Woodward Institute.  
 
Table 2. List of conditions selected for crystallization trials. 
Conditions for crystal trials Temp (°C) 
Crystallization 
method 
[MdfA] 
(mg/mL) 
Buffer used 
for MdfA 
0.39 M Zinc acetate, 0.1 M 
Sodium acetate, pH 5 
18 Hanging drop 4.5 MES buffer 
with 0.01% 
LMPG 0.1 M Zinc acetate, 0.1 M 
Sodium acetate, pH 5, 40% 
(w/v) PEG 400 
0.1 M Calcium acetate, 0.1 M 
Sodium acetate, pH 5, 20% 
(w/v) PEG 400 
0.05 M CsCl, 0.1 MES 
monohydrate, pH 6.5, 30% (v/v) 
Jeffamine M-600 
0.2 M CaCl2, 40% (v/v) MPD 
0.2 M CsCl, 40% (v/v) MPD 
MemSys Kit 4 and 
18 
Microbatch 
under oil 
4.5 MES buffer 
with 0.01% 
LMPG 
6.4 Phosphate 
buffer with 
0.01% LMPG 
4 and 
18 
2.8 MES buffer 
with 0.4% DDM 
 
 
 
3.7. Analytical methods  
3.7.1 Measurement of ATPase activity using Malachite Green assay 
ATPase activity of membrane and pure protein samples was tested in buffer B, using 2 
mM ATP (final concentration) over a time range of 15 min, at 37 °C.  Membrane samples were 
tested using 0.25 µg membrane protein, while for pure FoF1 ATPase, 0.1 µg was tested.  We 
measured the inorganic phosphate released upon ATP hydrolysis by FoF1 ATPase using the 
malachite green assay.  Reaction of inorganic phosphate with molybdate results in a complex 
that can be visualized colorimetrically using the dye, malachite green.  The protocol of Henkel 
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(Henkel et al., 1988) was used with the following modifications.  Malachite green reagent was 
made using 0.0406% (w/v) malachite green.  To determine whether the FoF1 ATPase was intact, 
ATPase activity was measured in the presence of the Fo domain inhibitor, DCCD.  Purified FoF1 
ATPase was incubated with 0.1 mM DCCD for 10 min at room temperature prior to testing 
ATPase activity.  A phosphate standard curve was prepared by measuring the malachite green 
and phosphomolybdate complex light absorption of 0, 10, 25, 50, 75, 100, 125 and 150 µM 
KH2PO4, in duplicate.  Forty microliters of samples or standards were mixed with 160 µL 
malachite green reagent, and incubated for 5 min at room temperature prior to absorbance 
measurement at 630 and 490 nm.     
 
3.7.2 Dye fluorescence assay for transmembrane H+-transport  
Since MdfA is a drug/H+ antiporter, MdfA substrate transport can be indirectly 
measured by observing proton transport using the fluorophore ACMA.  In theory, MdfA 
reconstituted into liposomes will transport substrates in the presence of a pH gradient.  A pH-
sensitive fluorophore, such as ACMA, can be used to monitor changes in pH, and thus 
indirectly monitor substrate transport by MdfA across a lipid bilayer.   
A fluorescence assay was performed as described (O'Grady, 2010) with changes noted.  
ACMA fluorescence was detected using an excitation wavelength of 410 nm and emission 
wavelength of 490 nm, with slit widths of 5 nm and 10 nm, respectively.  MdfA-reconstituted 
proteoliposomes were added to a buffer containing 10 mM Tricine-NaOH, pH 7.0, 5 mM 
MgSO4, and 50 mM Na2SO4, with 1 µM ACMA.  Valinomycin (EMD Inc.) and carbonyl 
cyanide 4-(trifluoromethoxy)-phenylhydrazone (FCCP) were added to final concentrations of 
12.3 nM and 25 nM, respectively, to generate a pH gradient.  Fluorescence restoration upon the 
addition of MdfA substrate, Cml, was measured.   
For optimization of the assay, various concentrations of FCCP (3-100 nM) valinomycin 
(1.1-12.3 nM), and proteoliposome amounts (10-250 µg) were tested to increase sensitivity of 
the assay to proton transport.  Following optimization, 15 µg of proteoliposomes by lipid 
content was used.  Cml was added to a final concentration ranging from 0-12 µM.   
FoF1 ATPase was also used as pH gradient generator, by co-reconstitution of FoF1 
ATPase and MdfA into preformed liposomes.  In this system, a pH gradient is created upon the 
addition of ATP.  ACMA was once again used to monitor changes in pH resulting from 
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substrate transport.  This assay was also used to confirm MdfA activity in E. coli cell 
membranes.  ACMA fluorescence was detected as before with slit widths of 10 nm and 1 nm, 
respectively.  ACMA was added to a final concentration of 2 µM and ATP, pH 7.5, was added 
to a final concentration of 2 mM.   
Membranes or proteoliposomes were added to 2 mL quench buffer B, quench buffer C 
(5 mM Tricine-KOH, pH 8.0, 5 mM MgCl2, 300 mM KCl, 1 mM DTT), quench buffer D (1 
mM Tricine-KOH, pH 8.0, 5 mM MgCl2, 300 mM KCl, 1 mM DTT), or quench buffer E (20 
mM Bis-Tris propane-MES, pH 8.0, 5 mM MgCl2, 1 mM DTT) in the presence of 100 nM 
valinomycin.  Valinomycin was not used in the case of quench buffer E.  The amount of 
proteoliposomes, and ATP and FCCP concentrations used varied as needed, and are indicated 
in chapter 4.   
A major challenge with proteoliposome formation is passive ion permeability due to 
poor detergent removal.  Standard experiments were performed in the presence of valinomycin 
in order for membrane potential to be discharged continuously throughout the assay.  As a 
result, it can be assumed that in a well-formed FoF1-ATPase reconstituted liposome, the rate of 
ΔpH generation will be slower if the membrane potential is not discharged by means of an 
ionophore.  If the liposome is not well-formed and is “leaky”, that is, it allows the passive flow 
of ions in the direction of thermodynamic equilibrium, the presence or absence of an ionophore 
will not affect the rate of ΔpH generation.  The membrane integrity of co-reconstituted 
proteoliposomes was tested by performing the assay in the absence of valinomycin.  Substrates 
tested were Cml, TPP+, NaCl, LiCl, IPTG (BioBasic Canada Inc.), benzalkonium, betaine 
(National Biochemical Corporation, Cleveland, Ohio), phenylalanine, tryptophan and 
phenylpropionate.  
 
3.7.3 Assay for fluorescent substrate transport using Ethidium bromide  
 Fluorescent MdfA substrates such as EtBr are incompatible with the assay set up 
described in 3.7.3.  To develop an assay system that exploits the inherent fluorescent properties 
of the substrates, we used EtBr.  We used MdfA-reconstituted proteolioposomes; however, a 
method of distinguishing between substrate inside and outside the liposome lumen was 
required.   EtBr fluorescence intensity is increased in the presence of double stranded DNA.  As 
a result, we entrapped double-stranded oligonucleotides inside the liposomes.  EtBr 
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accumulation inside liposomes would then result in an increase in fluorescence intensity 
proportional to the amount of EtBr transported into the liposomes.   
We prepared MdfA and FoF1-ATPase co-reconstituted liposomes as described in section 
3.4.2 with the following modifications:  10 µM oligonucleotides (5’-
TAATGAAAATGAAAGAAGATGGCAGTCGCTG-3’ and 5’-
CAGCGACTGCCATCTTCTTTCATTTTCATTA-3’) (Eurofins MWG Operon, Huntsville, 
Alabama) annealed to form double stranded DNA, and added to proteoliposomes following 
incubation of mixed liposomes at 25 °C and submitted to three freeze/thaw cycles as described 
earlier.  Proteoliposomes were collected by ultracentrifugation at 200,000 x g for 20 min at 4 
°C, resuspended in quench buffer B and extruded through a Whatman 400-nm polycarbonate 
membrane 20 times.  A pH gradient was generated using 2 mM ATP, and EtBr (EMD Inc.) 
transport was tested by addition of 0-10 µM EtBr to 1.25 mg liposomes.  EtBr fluorescence was 
detected using an excitation wavelength of 518 nm and emission wavelength of 605 nm, with 
both slit widths at 10 nm.  The proton gradient was uncoupled at the end of the assay by the 
addition of 4 µM FCCP.   
  
3.7.4 Other methods 
Protein concentration in the absence of imidazole was determined by the method of 
Lowry (Lowry et al., 1951) using bovine serum albumin (EMD Inc.) as a standard, with the 
following changes.  Sodium dodecyl sulfate (Roche Canada, Laval, Quebec) was added to a 
final concentration of 1% to fully dissolve and denature the protein.  Sodium citrate was used 
instead of sodium tartrate at the same concentration.  Absorbance measurements were taken at 
650 nm.  When buffers contained imidazole, protein concentration was determined by 
densitometry on Coomassie-stained SDS-PAGE gels (see below) using BSA as a standard.  
Densitometry experiments were performed using Syngene Chemigenius2, and GeneSnap 
version 6.03.   
 SDS-PAGE in 10% gels was performed according to Schägger and von Jagow 
(Schagger and Von Jagow, 1987).  SDS-PAGE gels were stained either with Coomassie R250 
or silver.  Silver staining procedure was performed as follows.  Gels were fixed first in 30% 
(v/v) ethanol, and 10% (v/v) acetic acid solution for 45 min, followed by incubation in 30% 
(v/v) ethanol and 6.8% (w/v) anhydrous sodium acetate for 30 min.  The gels were washed 
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three times in double distilled water for 5 min each.  They were then incubated in silver 
solution composed of 0.2% (w/v) AgNO3 (VWR International), and 0.0075 (v/v) formaldehyde 
for 20 min.  Bands were developed in a solution composed of 2.5% (w/v) NaCO3 (VWR 
International), and 0.0037% formaldehyde and the reaction stopped by incubation for 30 min 
with 0.5% (w/v) glycine (EMD Inc).  
Immunodetection of the histidine-tagged subunit a of FoF1 ATPase were performed 
according to manufacturer’s instructions (Qiagen).  Western blots of subunit c of FoF1 ATPase 
were performed using a polyclonal anti-subunit c antibody and an anti-rabbit antibody as a 
secondary antibody, according to Qiagen’s instructions for detection by secondary antibodies.  
All FoF1 ATPase purification samples for analysis by SDS-PAGE and Western blotting were 
prepared by acetone precipitation.  Protein samples wer added to acetone at a 1:4 (v/v) ratio, 
mixed well, and centrifuged at 12,000 x g for 10 min.  The supernatant was discarded and the 
pellet was dried at 37 °C.  The pellet was resuspended in sample buffer and incubated at 95 °C 
for 5 min prior to loading.  MdfA samples were diluted in sample buffer prior to loading, but 
not heat-treated.   
MdfA purified in 0.005% (w/v) LMPG and 0.4% (w/v) DDM was analyzed by DLS 
using the DynaPro/Micro Sampler with Dynamics Software package version 5.26.60.   
4. Results 
4.1 MdfA purification and characterization for structural studies 
Our lab had developed a purification procedure for MdfA prior to the start of this 
project (O'Grady, 2010).  In this protocol, MdfA was overexpressed in E. coli, and purified 
from the cell membranes by Ni2+-affinity chromatography using LMPG, DHPC, and DDM for 
structural and functional characterization.  Note that DHPC or DDM was used to disrupt cell 
membranes, and that the detergent was exchanged on the column during the purification into 
the desired final detergent (Fig. 4.1).  SDS-PAGE analysis of MdfA purification in LMPG, 
DDM, and DHPC showed a band corresponding to MdfA at 31 kDa, as expected based on 
previous studies (Fig. 4.2).  Average protein yield was 0.9 mg MdfA per liter cell culture, and 
protein purity of MdfA in LMPG was determined to be 80%.  Since in all cases, except with 
initial DDM purification of MdfA, membrane solubilization was performed with DHPC, MdfA 
yields were similar regardless of final detergent used (Fig 4.2).   
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In order to minimize non-specific detergent-substrate interactions in kinetic studies and 
to enhance crystal contacts in structural studies, we sought to optimize the LMPG and DDM 
concentrations used for MdfA purification.  LMPG concentrations ranging from 0.005%-0.2% 
(w/v) were tested in both TMDG and KPi buffers by detergent exchange on a Ni-NTA column 
(Fig 4.3).  A given detergent concentration was determined to solubilize MdfA if it could be 
used for both protein purification and concentration.  In SDS-PAGE, MdfA migrates at 31 kDa.  
In these gels, a single band at 31 kDa in the lane corresponding to pure MdfA indicated pure, 
soluble protein (Figs. 4.2-5).  For purification in TMDG buffer, MdfA was soluble in 0.005% 
LMPG (Fig. 4.3), while purifications using KPi buffer required at least a concentration of 
0.01% LMPG.  DDM concentrations ranging from 0.02-0.4% (w/v) were tested in TMDG 
buffers.  MdfA was soluble in a concentration of DDM as low as 0.02% (Fig 4.4).     
To improve the yield and purity of MdfA, an imidazole gradient elution was performed 
using an ÄKTA FPLC.  Imidazole gradients from 20-500 mM were used, in the presence and 
absence of 500 mM NaCl; however, neither modification improved MdfA purity or yield (data 
not shown).   
Based on a search of the Membrane Protein Data Bank, OG, LDAO, and C12E8 were 
selected as potential detergents for MdfA solubilization (Table 1) (Raman et al., 2006).  
Detergent exchange was performed by successive washes with the detergent of interest, prior to 
protein elution from the column (Fig. 4.2).  OG, LDAO, and C12E8 were tested (Fig. 4.5).  
MdfA was found to be soluble in all three detergents.  However, attempts to concentrate MdfA 
in OG or LDAO detergent micelles immediately resulted in precipitation, indicating that MdfA 
is not soluble in either OG or LDAO at the required protein concentration (Fig. 4.5B).   
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Figure 4.1. Standard protocol for MdfA expression in E. coli and purification from whole 
cell membranes. 
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Figure 4.2.  MdfA purification steps in different detergents analyzed by SDS-PAGE. 
Note that MdfA migrates at an apparent molecular weight of 31 kDa on an SDS-
PAGE gel.  Purifications were performed using a Ni-NTA column.  All gels in this 
figure were stained with Coomassie R-250. 
A. Purification of MdfA in 0.2% LMPG using TMDG buffer.  Lane 1, 35 µg 
membrane protein solubilized in 2% DHPC; lane 2, detergent-soluble fraction; lane 3, 
column load sample; lane 4, column load flowthrough; lane 5, column wash using 
0.4% DHPC; lane 6, column wash using 0.2% LMPG; and lanes 7-9, 2 mL column 
fractions of MdfA elution using 0.2% LMPG.  For lanes 3-4, 3.5 µL was loaded, while 
for lanes 4-9, 7.5 µL of each column wash or fraction was loaded. 
B. Purification of MdfA in 0.4% DHPC in KPi buffer.  Lane 1, 75 µg membrane 
protein solubilized in 2% DHPC; lane 2, detergent-soluble fraction; lane 3, column 
load sample; lane 4, column load flowthrough; lane 5, column wash using 0.4% 
DHPC; and lane 6, MdfA elution in 0.4% DHPC.  For all lanes, 7.5 µL of each 
supernatant or column wash was loaded.   
C. Purification of MdfA in 0.4% DDM using TMDG buffer.  Lane 1, 50 µg membrane 
protein solubilized in 2% DDM; lane 2, detergent-soluble fraction; lane 3, column 
load sample; lane 4, column load flowthrough; lane 5, column wash using 0.4% DDM; 
and lane 6, MdfA elution in 0.4% DDM.  For lanes 2-6, 5 µL of each supernatant or 
column wash was loaded.  
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Figure 4.3.  Effect of various concentrations of LMPG on MdfA solubility.  Coomassie-
stained SDS-PAGE gel of Ni-NTA column eluants in TMDG buffer.  Lane 1, 0.005% 
LMPG; lane 2, 0.01% LMPG; lane 3, 0.02% LMPG; and lane 4, 0.2% LMPG.  Samples 
were equalized by volume prior to loading.   
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Figure 4.4. MdfA purification in 0.02% DDM.  Coomassie-stained SDS-PAGE gel of 
Ni-NTA column fractions in TMDG buffer.  Note that MdfA migrates at an apparent 
molecular weight of 31 kDa.  Lane 1, column load sample; lane 2, column load 
flowthrough; lane 3, column wash using 0.4% DHPC; lane 4, column wash using 0.02% 
DDM and 20 mM imidazole; lane 5, MdfA elution in 0.02% DDM.  For lane 1, 15 µg 
protein was loaded, while for lanes 2-5, 7.5 µL of each sample was loaded.   
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4.2 FoF1 ATPase purification 
Since MdfA is a H+/drug antiporter, a proton gradient is required to study its transport 
function across a membrane.  In order to use the E. coli FoF1 ATPase to generate a proton 
gradient via hydrolysis of ATP to ADP in proteoliposomes with co-reconstituted FoF1 ATPase 
and MdfA, we purified FoF1 ATPase from E. coli by PEG fractionation.   An FoF1 ATPase 
purification from P. modestum by PEG fractionation has been reported (Laubinger and 
Dimroth, 1988).  To use this protocol in E. coli, three parameters were optimized: the 
protein:detergent ratio used for membrane solubilization, detergent type, and PEG 
concentration.   
Figure 4.5. Coomassie-stained SDS-PAGE gels of MdfA purification using OG, C12E8, 
and LDAO.  Note that MdfA migrates at an apparent molecular weight of 31 kDa.  A. 
Load, 22 µg detergent-soluble membrane protein prior to detergent exchange.  Lane 1, 
load flowthrough; lane 2, column wash with 0.4% DHPC; lane 3, wash with excess OG, 
C12E8 or LDAO; and lanes 4 and 5, wash and elution, respectively, with 1.75% OG, 
0.013% C12E8 or 0.07% LDAO.  Gels were loaded with 11.25 µL of each column wash 
and final eluant.  B. OG and LDAO precipitates were resuspended in buffer volumes 
equal to the supernatant volume, and 11.25 µL of each supernatant and precipitate were 
loaded.  Lanes 1 and 3, supernatants from MdfA in OG and LDAO, respectively.  Lanes 2 
and 4, resuspended precipitates from MdfA in OG and LDAO.   	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Wild type FoF1 ATPase was overexpressed in E. coli.  E. coli membranes were prepared 
by ultracentrifugation (O’Grady, 2010).  Membranes were then solubilized at ratios of 2.5, 5.0, 
or 10.0 mg protein/mL buffer, and Triton-X 100 concentrations of 0.5, 1.0, 1.5, 2.0, and 2.5% 
(w/v) (Fig. 4.6).  Extracts prepared under these solubilization conditions were then analyzed by 
SDS-PAGE and Western Blot (Fig. 4.6).  Solubilization was determined visually by the 
intensity of the bands corresponding to subunits α and β of the ATPase in the gel, and the 
disappearance of the subunit a band in lanes corresponding to insoluble fraction in the Western 
Blot.  We selected 5.0 mg protein/mL buffer and 2.0% Triton-X 100 as optimal protein and 
detergent concentrations since this was the highest protein concentration at which the majority 
of protein was successfully solubilized (Fig. 4.6B).  
This extract was submitted to PEG 6000 fractionation in the presence of 50 mM MgCl2, 
at PEG concentrations ranging from 2.0-12.0% (w/v), and analyzed by SDS-PAGE and 
Western Blot.  Fractionation was tracked by observation of the intensity of bands corresponding 
subunits α and β of the ATPase in the gel, and the subunit a band in the Western Blot.  For PEG 
precipitation of contaminating proteins, 2.0% PEG was found to be the optimal concentration, 
since a majority of the FoF1 ATPase remained soluble, but much of the other membrane 
proteins were precipitated (Fig. 4.7).  For FoF1 ATPase precipitation, 10.0% PEG was found to 
be ideal, since it was the lowest concentration of PEG at which a majority of the ATPase was 
precipitated (Fig. 4.7).   
 In this E. coli construct, subunit a of the FoF1 ATPase is His-tagged.  We attempted 
further purification of the protein complex by imidazole gradient elution using a Qiagen Ni-
NTA superflow column.  Analysis by SDS-PAGE and Western Blot showed partial dissociation 
of the enzyme complex into individual subunits.  These results indicated that Triton-X 100 is 
not a suitable detergent for purification of the E. coli FoF1 ATPase (data not shown). 
To find conditions that would preserve the stability of the enzyme complex, we tested 
ATPase activity by measuring inorganic phosphate accumulation over time using the Malachite 
green assay.  Protein samples from various steps of the purification protocol were tested in the 
presence and absence of the Fo inhibitor, DCCD.  ATPase activity of the E. coli membranes 
was 1.7 U/mg with DCCD sensitivity of 93% (Fig. 4.8A).  The purified FoF1 ATPase showed 
ATPase activity of 4.1 U/mg, corresponding to 96% recovery of activity, but it was not 
sensitive to inhibition by DCCD, indicating that the Fo and F1 domains are uncoupled (Fig. 
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4.8B).  These results suggested that our purification procedure has a destabilizing effect on the 
complex. 	  We next tested the effect of 2.0% Triton-X 100 (w/v), 2.0% OG (w/v), 1.0% DHPC 
(w/v) and 0.2% DHPC (w/v) on the FoF1 ATPase by preparing membrane extracts using these 
detergents.  These extracts were then tested for ATPase activity and DCCD-sensitivity using 
the Malachite green assay.  DCCD-sensitive ATPase activity was found only in 0.2% DHPC 
(Fig. 4.8A).  This extract was applied directly to a nickel column and imidazole gradient elution 
was performed.  However, analysis of the collected fractions by SDS-PAGE and Western Blot 
indicates that the protein complex was not stable on the column (data not shown).   
Figure 4.6. Analysis of Triton-X 100 solubilization of E. coli membranes for FoF1 ATPase 
purification at various detergent:protein ratios.  A. Coomassie-stained SDS-PAGE gel.  
Subunits α (55.3 kDa) and β (50.3 kDa) were used to track FoF1 ATPase precipitation and are 
indicated by arrows. B. Subunit a detection by Western Blot.  Low molecular weight markers 
are shown at left.  Lanes 1, 4, 7, 10, membranes with detergent added; lanes 2, 5, 8, 11, 
detergent-soluble fraction; lanes 3, 6, 9, 12, insoluble protein.  Sample volumes were 
normalized to account for the dilution factor, and 7.5 µL of each was loaded.  
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Fortunately, PEG precipitation of the 0.2% DHPC extract resulted in a stable FoF1 
ATPase.   The FoF1 ATPase in 0.2% DHPC was determined to have a specific activity of 3.8 
U/mg, corresponding to 89% recovery of activity, relative to E. coli membranes, and was  
sensitive to inhibition by 0.1 mM DCCD (Fig. 4.9A).  Protein purity was determined by 
densitometry.  Comparison of bands corresponding to subunits of FoF1 ATPase, with the total 
density of bands appearing in the lane corresponding with pure protein in the SDS-PAGE gel  
 
Figure 4.7.  Analysis of PEG 6000 concentrations for selective fractionation of FoF1 ATPase. 
Subunits of the ATPase and their molecular weights are as follows: α (55.3 kDa), β (50.3 
kDa), γ  (31.6 kDa), a (30 kDa), δ (19.3 kDa), b (17 kDa), ε (14.9 kDa), and c (8.2 kDa). 
Membranes were diluted to 5.0 mg/mL and disrupted using 2.0% Triton-X 100.  The 
detergent-soluble fraction was concentrated threefold, and fractionated using 0, 2, 4, 6, 8, 10, 
12% PEG 6000 (final concentration) as indicated.  “S” refers to soluble fraction, and “I” 
refers to insoluble fraction.  Sample volumes were normalized to account for the dilution 
factor.  (A) Coomassie-stained SDS-PAGE gel.  Arrows indicate subunits of the FoF1 
ATPase.  (B) Subunit a detection by Western blot.   
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Figure 4.8.  Characterization of FoF1 ATPase activity and DCCD-sensitivity in 0.05% 
Triton-X 100 in comparison to E. coli membranes.  Inorganic phosphate accumulation over 
time in the presence (red) and absence (blue) of DCCD, an Fo inhibitor. ATP hydrolysis 
activity of FoF1 ATPase in E. coli cell membranes (A) and in 0.05% Triton-X 100 detergent 
micelles (B).  Linear fit line was obtained by linear regression in MS Excel.     
 
Figure 4.9.  Analysis of FoF1 ATPase in 0.2% DHPC using the Malachite green assay and 
Coomassie-stained SDS-PAGE.  The bands which correspond to subunits of the FoF1 ATPase 
are indicated by arrows, and are as follows: α – 55.3 kDa, β – 50.3 kDa, γ – 31.6 kDa, a – 30 
kDa, δ – 19.3 kDa, b – 17 kDa, ε – 14.9 kDa, and c – 8.2 kDa.  A. Inorganic phosphate 
accumulation over time in the presence (red) and absence (blue) of DCCD, an Fo inhibitor.  
Linear fit was obtained by linear regression in MS Excel.   B. SDS-PAGE gel of FoF1 
purification using 0.2% DHPC.  Low molecular weight standards are shown at left.  “S” 
indicates supernatant, while “P” indicates pellet.  Lanes 1, membrane extract; 2, 2% PEG 
precipitation; 3, 10% PEG precipitation; 4, PEG pellet resuspended in buffer B.  Lane 1S has 
~40 µg protein loaded. Lanes 1P, 2, and 3 were equalized for volume with lane 1S, and 10 µL 
of each was loaded.  Lane 4S was loaded with 26 µg protein, and lane 4P was equalized by 
volume with 4S.  FoF1 purity in lane 4S is estimated to be 60%, by comparison with lane 1S.  
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showed that the final sample had a purity of 60% (Fig. 4.9B).  The final protein yield was 0.5 
mg FoF1 ATPase/L cell culture.  These results indicated that this purification procedure was 
sufficient for use in co-reconstitution studies with MdfA.   
 
 
4.3. Fluorescence based substrate transport assays 
4.3.1 MdfA activity in E. coli whole cell membranes 
 We sought to develop a simple general assay to test the substrate profiles of putative MFS 
multidrug transporters.  Prior to the start of this project, an assay that couples proton 
translocation to fluorescence was developed in our lab (O’Grady, 2010).  Since MdfA is a 
H+/drug antiporter, proton translocation is an indirect way of measuring drug transport.  In this 
assay, MdfA-reconstituted proteoliposomes, pre-loaded with potassium at an internal pH of 7.0, 
are added to a potassium-free buffer, also at pH 7.0.  In this state, the pH-sensitive fluorescent 
probe, ACMA, will freely diffuse across the liposome membrane.  Upon the addition of 
valinomycin, the membrane becomes permeable to K+ ions, and an electric potential difference 
is created.  The addition of FCCP allows for protons to dissipate this electric potential 
difference, while creating a pH difference across the membrane.  Protonated ACMA cannot 
cross the liposome membrane.  The charged ACMA molecules are trapped in the liposome 
lumen, and ACMA fluorescence is quenched in a concentration dependent manner.  When 
MdfA substrate is added to the buffer, MdfA will exchange substrate for protons in a 1:1 ratio, 
decreasing the transmembrane pH-gradient.  ACMA molecules will then be able cross the 
liposome membrane, and fluorescence will be restored (Fig. 4.10).   
Conditions such as buffer composition, liposome amount, the concentrations of FCCP 
and valinomycin for this assay were optimized (data not shown).  Though MdfA-reconstituted 
proteoliposomes showed fluorescence restoration that correlated with Cml concentration, 
experiments with control liposomes showed similar effects (Fig. 4.11).  In these experiments, 
ethanol was used as a solvent for Cml.  Control experiments were performed to determine if 
ethanol affected liposome stability, and, as a result, was responsible for the observed 
fluorescence restoration.  Liposomes that had not been treated with detergent were also tested.  
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Cml on fluorescence restoration (data not shown).  We concluded from these experiments that a 
more robust assay system was required to test putative MDT.  Such a system must be able to 
generate reproducible pH gradients, indicated by similar fluorescence quenching, and cannot be 
sensitive to substrates in the absence of transporter.  
The method of generating the ΔpH is not important for this assay to function.  However, 
it is critical that the assay be easily reproducible and amenable to fine-tuning of the gradient.   
ATP hydrolysis by FoF1 ATPase can be used to generate a pH gradient, and the pH- difference 
across the membrane is controlled by the amount of ATP in the system.  As a result, we co-
reconstituted FoF1 ATPase and MdfA into proteoliposomes to study MdfA activity.  In this 
assay, reconstituted proteoliposomes are added to quench buffer.  The proteoliposome lumen 
contains 25 mM potassium, and is at pH 7.0, while the buffer has 300 mM potassium, and a pH 
of 8.0.  Valinomycin is added to discharge the electric potential difference that is generated 
upon the transport of protons by FoF1 ATPase into the liposome lumen.   ACMA is added, and 
fluorescence is observed.  As stated earlier, neutral ACMA freely crosses the membrane.  Upon 
the addition of ATP, FoF1 ATPase hydrolyzes ATP and transports protons across the 
membrane, creating a pH gradient.  Protonated ACMA is trapped in the liposome lumen, and 
ACMA fluorescence is quenched in a concentration-dependent manner.  Fluorescence can then 
be restored by dissipating the proton gradient, either by the addition of MdfA substrate or the 
addition of FCCP (Fig. 4.12). 
To validate the general assay design, we transport of a known MdfA substrate, Cml, in 
MdfA-induced and uninduced whole cell membranes.  A proton gradient was generated using 
ATP hydrolysis by endogenous FoF1 ATPase, and the effect of Cml addition on fluorescence 
was observed.  We expected that fluorescence would increase if Cml transport were occurring.  
Indeed, in MdfA-induced cell membranes, Cml transport was observed at concentrations 
ranging between 20-200 µM, while in uninduced cells, no Cml transport was observed (Fig. 
4.13-14).  Quench buffer was used as a solvent for Cml in these experiments; control 
experiments with buffer showed no effect on fluorescence (Fig 4.13-14).   
Uninduced cell membranes showed a slightly decreased rate and extent of ATP-
dependent fluorescence quenching than induced cell membranes (Fig. 4.13).  The reasons for 
this are unknown.  However, it is likely that this difference in the extent of pH gradient  
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Figure 4.10.  Principle of the proton-coupled fluorescence assay using MdfA-reconstituted 
proteoliposomes.   1. ACMA freely diffuses across the proteoliposome membrane in 
unprotonated (electroneutral) form.  2. Valinomycin allows K+ to flow out down its 
concentration gradient, creating an electrical potential difference across the liposome 
membrane.  3. FCCP allows H+ entry into the liposome driven by the electric potential 
difference.  This creates a pH-difference across liposome membrane (acidic inside).  
ACMA is protonated in a low pH environment and is trapped in the proteoliposome 
lumen, causing a concentration-dependent fluorescence quenching.  4. The addition of an 
MdfA substrate to the system causes the coupled transport of a substrate molecule in and 
of a proton out.  The previously trapped ACMA molecules are deprotonated and diffuse 
out of the proteoliposome resulting in a fluorescence increase. 
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generation would not affect the observation of MdfA-independent Cml transport, and no Cml 
transport was observed (Fig. 4.13-14).   
Interestingly, concentrations of Cml greater than 100 µM do not result in increased 
levels of fluorescence restoration (Fig. 4.14).  It is possible that this occurs because high 
concentrations of Cml have an inhibitory effect on MdfA.  Another less likely possibility is that 
at these concentrations, MdfA transports Cml out of, and protons into, the liposome lumen.  
Cml is hydrophobic and would readily intercalate into the liposome membrane.  In that case, 
transport in the substrate-in/proton-out direction would still exist, but would be at a lower, and 
therefore less detectable, rate than the reverse reaction.   
The objective of these experiments was to validate the assay system and to determine if 
MdfA was active in whole cell membranes.  We conclude that the assay system designed is 
valid and can be used for the substrate profile determination of putative multidrug transporters.  
However, it must be noted that, especially for hydrophobic compounds, concentrations above 
200 µM may give false negative results.  These experiments also show that MdfA is active in 
whole cell membranes.   
 
 
 
Figure 4.11.  ACMA fluorescence restoration upon the addition of Cml to MdfA-reconstituted 
proteoliposomes (A) and liposomes without reconstituted protein (B).  Energy for MdfA 
substrate transport was generated by conversion of a potassium gradient to a proton gradient 
using valinomycin and FCCP.  The amount of Cml added is indicated in the legend.  Cml was 
added to all samples at 200 s. 
	   64	  
 
 
   
 
Figure 4.12.  Illustration of proton-coupled fluorescence assay using MdfA and FoF1 
ATPase co-reconstituted proteoliposomes.  1. ACMA freely diffuses across the 
proteoliposome membrane in unprotonated (electroneutral) form.  2. The addition of 
ATP causes protons to be actively pumped into the liposome lumen by hydrolysis of 
ATP to ADP creating a pH difference across the membrane (inside acidic).  In this low 
pH environment, ACMA molecules are protonated and unable to cross the membrane; 
as a result, ACMA fluorescence is quenched in a concentration-dependent manner. 3. 
When an MdfA substrate is added to the system, MdfA will use the energy of the proton 
gradient to pump substrate into the liposome lumen in exchange for a proton.  The pH 
gradient will decrease, causing ACMA molecules to become deprotonated, and able to 
cross the membrane, resulting in an increase in fluorescence.   
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Figure 4.13.  Transport of Cml by MdfA in E. coli whole cell membranes.  A sample set of 
fluorescence traces showing ACMA fluorescence quenching upon the generation of a proton 
gradient by ATP hydrolysis, and restoration upon the addition of 100 µM Cml to 100 µg 
membranes.  FCCP, a proton gradient uncoupler, was added as a control.  All additions are 
indicated by arrows. Red, MdfA-induced membranes with buffer added; blue, MdfA-induced 
membranes with Cml added; green, MdfA-uninduced membranes with Cml added.  All 
experiments were performed in duplicate.  Note that the experiments shown here were 
performed using 0.75 mM ATP.  
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Figure 4.14. Detailed view of transport of 0-500 µM Cml catalyzed by MdfA in E. coli cell 
membranes.  Cml transport by overexpressed MdfA in E. coli membranes was tested by 
measuring ACMA fluorescence restoration over time. Additions of Cml or buffer are 
indicated by black arrows.  All experiments were performed in duplicate, though only one 
representative set is shown.  Note that these experiments were performed using 0.75 mM 
ATP.  
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4.3.2 Functional co-reconstitution of FoF1 ATPase and MdfA for drug transport 
measurements 
In order to develop an assay with greater MDT-specific sensitivity to substrates, we 
sought to generate a pH-gradient using FoF1 ATPase, as described in section 4.3.1 (Fig. 4.12). 
To test and optimize FoF1 ATPase-reconstitution into proteoliposomes, FoF1 ATPase was 
reconstituted into liposomes at 0, 1:40, 1:80, or 1:200 (w/w) protein:lipid ratios.  Protein 
reconstitution was achieved by detergent disruption of preformed liposomes and incubation 
with protein followed by detergent removal by Bio-Beads.  Amounts of liposomes added to 
quench buffer B were increased from 100 µg to 500 µg until complete fluorescence quenching 
was achieved.  By observing the rate and extent of fluorescence quenching, the fraction of 
liposomes that have successfully reconstituted FoF1 ATPase can be estimated.  At a 
protein:lipid ratio of 1:40, an adequate rate and extent of quench was observed at both 100 µg 
and 250 µg proteoliposomes (Fig. 4.15).  Other protein:lipid ratios showed slower quench rates 
(data not shown).  All future experiments, under these conditions, were performed with 125 µg 
liposomes at a 1:40 protein:lipid ratio.  
Proteoliposome membrane integrity was tested by performing this assay in the absence 
of valinomycin.   Upon the addition of ATP, FoF1 ATPase will pump protons into the liposome 
lumen, generating both ΔpH and Δψ across the membrane.  The addition of valinomycin 
discharges Δψ, allowing the FoF1 ATPase to generate a higher ΔpH at the same value of ΔµH, as 
determined by the ΔG of ATP hydrolysis.  In the absence of valinomycin, FoF1 ATPase will 
still show some proton transport into the liposome lumen upon the addition of ATP to the 
system.  However, this rate should be much slower than if the electrical potential difference is 
removed through the addition of valinomycin.  Indeed, experimental results show that in the 
absence of valinomycin, both the rate of fluorescence quenching and uncoupling of the pH 
gradient by the addition of FCCP were significantly decreased (Fig. 4.16). 
To determine the optimal MdfA:lipid ratio for these experiments, MdfA was 
reconstituted into FoF1 ATPase-reconstituted proteoliposomes (1:40 w/w) at a protein:lipid ratio 
of 0, 1:80, or 1:240 (w/w).  Decreased fluorescence quenching was observed at a protein:lipid 
ratio of 1:80, possibly due to interfering effects of reconstituting a large amount of protein; 
however, reconstitution at 1:240 showed a fluorescence quenching rate comparable to MdfA-
free liposomes (Fig. 4.17A).  The addition of 100 µg/mL (310 µM) Cml shows a slight increase 
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in fluorescence in MdfA-reconstituted proteoliposomes, indicating successful MdfA 
reconstitution (Fig. 4.17B).  Decreasing the concentration of ATP slowed the rate of 
fluorescence quenching, but did not affect fluorescence restoration upon the addition of Cml 
(data not shown).   
To improve sensitivity of the assay to substrate transport, and reproducibility between 
experiments, we sought a different strategy for protein reconstitution.  Detergent-mediated 
reconstitution by dialysis has previously been successful with MFS type transporters such as 
LacY and GlpT (Poolman and Konings, 1993).  Both strategies of detergent removal (Bio-
Beads and dialysis) involve incubation of protein with detergent destabilized preformed 
liposomes, but it is possible that the hydrophobic Bio-Beads bind MdfA and therefore interfere 
with reproducibility.  We developed a dialysis protocol for the co-reconstitution of MdfA and 
FoF1 ATPase.  Following dialysis, we performed three cycles of freezing in liquid nitrogen and  
 
 
Figure 4.15. ACMA fluorescence quenching in FoF1 ATPase-reconstituted 
proteoliposomes (1:40 w/w protein:lipid).  Additions of ACMA, ATP and FCCP are 
indicated by arrows.  Green – 250 µg empty proteoliposomes; red – 250 µg 
proteoliposomes; and blue – 100 µg proteoliposomes.  Note that the experiments shown 
here were performed using 2 mM ATP.  
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Figure 4.16. Increasing protein:lipid ratio in FoF1 ATPase-reconstituted proteoliposomes 
enhanced rate of ATP-dependent fluorescence quenching. A. ATP-dependent fluorescence 
quenching in the presence of valinomycin. B. ATP-dependent fluorescence quenching in the 
absence of valinomycin. Blue – liposomes without protein; red – FoF1 ATPase liposomes 
reconstituted at a 1:40 (w/w) protein:lipid ratio; green – liposomes reconstituted at a 1:80 
(w/w) protein:lipid ratio; and purple – liposomes reconstituted at a 1:200 (w/w) protein:lipid 
ratio.  Note that the experiments shown here were performed using 2 mM ATP.  
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thawing at 25 °C, in order to improve protein and distribution among liposomes.  Freeze/thaw 
cycles cause the fusion and fission of liposomes, and, ideally, will decrease heterogeneity 
among proteoliposomes.  The optimal protein:lipid ratios for FoF1 ATPase and MdfA 
reconstitution were determined as described above.  We sought protein:lipid ratios at which the 
proton gradient, as detected by ACMA fluorescence quenching, was most sensitive, so that any 
substrate/proton exchange by MdfA would be detected.  The optimal FoF1 ATPase: lipid ratio 
was 1:80 (w/w), while the optimal MdfA:lipid ratio was 1:40 (w/w) (data not shown).   
Furthermore, we performed sucrose density fractionation of the co-reconstituted 
proteoliposomes to determine the efficiency of the dialysis-mediated reconstitution protocol.  
For all fractions, we performed SDS-PAGE and Western blotting to detect protein, and 
turbidity measurements to detect liposomes (Fig. 4.18).  We expected that in a system in which 
protein reconstitution is occurring, protein and liposomes would be found in the same fractions.  
Analysis of reconstituted liposomes with and without MdfA demonstrated that while 
reconstitution of FoF1 ATPase was optimal, MdfA co-reconstitution was not ideal (Fig. 4.18).  
From these experiments, it was not clear whether FoF1 ATPase is better able to be reconstituted 
into liposomes during dialysis or if steric effects from FoF1 ATPase prevented co-reconstitution 
with MdfA.  However, it was clear that co-reconstitution needed optimization.   
We optimized the reconstitution protocol by first reconstituting each protein into 
liposomes individually, and then mixing them at specific ratios (w/w lipid) by freeze/thaw 
cycles to achieve co-reconstitution.  The ideal conditions, as shown by fluorescence assays of 
various ratios, were at 4:1 MdfA-reconstituted proteoliposomes and FoF1 ATPase-reconstituted 
proteoliposomes (Fig. 4.19).  In these experiments, 0.1 mM ATP was found to be non-
saturating; that is, if a lower concentration of ATP were used, FoF1 ATPase would not maintain 
the fluorescence quench.  In theory, a non-saturating concentration of ATP would allow for 
greater sensitivity to the detection of substrate/proton exchange by MdfA.  
We did not observe Cml transport under these conditions (Table 3).  However, in 
theory, the conditions in this setup are ideal.  Since it was possible that MdfA transport activity 
is higher with a different substrate, we tested a variety of known MdfA substrates, and known 
MFS transporter substrates by MdfA under these conditions (Table 3).  Transport was not 
observed for any substrate tested.   
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Figure 4.17. Fluorescence assays of co-reconstituted proteoliposomes at various 
MdfA:lipid ratios.  A. Effect of increasing the MdfA:lipid ratio on the rate and extent of 
fluorescence quenching.  B. Upon the addition of 100 µg/mL Cml (at 160 s), fluorescence 
is slightly restored.  Inset, fluorescence restoration upon the addition of Cml.  Addition of 
ACMA, ATP, Cml, and FCCP are indicated by arrows.  Blue – liposomes without MdfA; 
red – MdfA and FoF1 ATPase-reconstituted proteoliposomes, MdfA:lipid = 1:80 (w/w); 
and green - MdfA and FoF1 ATPase-reconstituted proteoliposomes, MdfA:lipid = 1:240 
(w/w). 
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Figure 4.18. Sucrose density fractionation of FoF1 ATPase (A) and FoF1 ATPase and MdfA 
co-reconstituted (B) proteoliposomes.  Reconstituted proteoliposomes were fractionated on a 
45-10% (w/w) sucrose gradient.  Top: Turbidity measurements at OD600 of all fractions.  
Middle: Silver-stained SDS-PAGE gels of all fractions.  Bottom: Anti-His blot of subunit a 
from FoF1 ATPase and MdfA of all fractions.    
Figure 4.19.  Optimization of MdfA and FoF1 ATPase co-reconstitution by mixing 
proteoliposomes at various ratios (w/w).  Each sample contained a total of 125 µg liposomes. 
Ratios of MdfA-containing proteoliposomes to FoF1 ATPase-containing proteoliposomes are 
indicated in the legend.  Additions of ACMA, ATP and FCCP are indicated by arrows.  
Assays shown here were performed using 0.1 mM ATP.   
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Further attempts at optimization did not yield improved results.  The standard buffer 
used was composed of 20 mM Tricine-KOH, pH 8.0, 5 mM MgCl2, and 300 mM KCl.  We 
tested buffers with decreased pH-buffering capacity, (5 mM Tricine-KOH, pH 8.0 and 1 mM 
Tricine-KOH, pH 8.0).  MdfA is also known to have some K+/H+ transport function.  As a 
result, we also tested a potassium-free buffer composed of 20 mM Bis-Tris propane-MES, pH 
8.0.  However, these buffer compositions prevented the generation of a fluorescence quench, 
and it was not possible to test substrate transport by MdfA under these conditions (data not 
shown).     
 
 
Table 3. Substrates tested for transport by MdfA in FoF1 ATPase and 
MdfA co-reconstituted proteoliposomes. 	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4.3.3 Ethidium bromide transport experiments in FoF1 ATPase and MdfA co-
reconstituted proteoliposomes 
The fluorescence assay described above is compatible with a wide variety of potential 
substrates; however, it has limited applications when the substrates themselves are fluorescent.   
For example, EtBr is a known MdfA substrate with absorption maxima at 518 nm (DNA-
bound) or 480 nm (free EtBr in water).  ACMA, on the other hand, is excited at 410 nm and 
emits photons at 490 nm.  Thus, if EtBr was added to the assay system described above, the 
emission of photons from ACMA would simply excite the molecules of EtBr, and a true 
reading would not be obtained.  This is known as the inner filter effect (Lakowicz, 2006).   
As a result, an EtBr-specific assay was required.  We designed an assay that exploits the 
fluorescence intensity increase when EtBr binds DNA.  In theory, double-stranded 
oligonucleotides can be encapsulated into the proteoliposomes with co-reconstituted MdfA and 
FoF1 ATPase.  In the assay, following the generation of a proton gradient by the addition of 
ATP, EtBr is added at the desired amount.  EtBr outside the liposome would fluoresce at a 
lower intensity than any EtBr that would be transported into the liposome by MdfA since EtBr 
inside would readily bind DNA.  It would then be possible to monitor EtBr transport by 
observing changes in fluorescence intensity.  However, we did not observe any difference in 
fluorescence between liposomes with and without reconstituted MdfA (Fig. 4.20).    
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Figure 4.20. DNA-bound EtBr fluorescence intensity in proteoliposomes with and without 
MdfA.   
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4.4. NMR experiments for measurement of substrate binding to MdfA 
4.4.1 Acetyl chloramphenicol synthesis and characterization  
 
MdfA is a 45 kDa protein, and is too large to obtain useable NMR spectra. However, 
small molecules such as drugs can be labeled with NMR-active isotopes such as 13C or 15N, and 
their interactions with MdfA can be detected by monitoring chemical shift perturbations or 
linewidth broadening of the reporter group.  We labeled Cml with a 13C isotope for use in NMR 
studies. 13C-labeled chloramphenicol was synthesized by acetylation of chloramphenicol with 
13C-acetyl chloride as described by Derrick et al. (Derrick et al., 1991).  Both mono- and di-
acetylated chloramphenicol were synthesized, and separated by thin layer chromatography.  
AcCml synthesis was confirmed by proton NMR (Fig. 4.21).  The spectrum revealed several 
extraneous peaks (7.412, 5.159, 4,424, and 2.703 ppm), which are likely to be impurities (Fig. 
4.21).  As expected, one of the CH3 peaks, at 2.22 ppm, was not observed, since mono-acetyl 
Cml was analyzed (Fig. 4.21).  However, the CHCl2 peak was shifted from 6.25 ppm to 6.145 
ppm (Fig. 4.21).  We suspect that this shift is due to the use of acetonitrile as the solvent.  
Derrick and coworkers used phosphate buffer (pH 7.5) as a solvent for their experiments.  We 
were unable to do the same due to the extreme hydrophobicity of the product.   
To confirm the concentration of 13C-AcCml, a calibration curve was produced using 
NMR by measuring the 13C-acetyl-15N-glycine (NAG) peak intensities as a function of NAG 
concentration.  NAG has two sites that are detectable using 1H,13C-HSQC experiments, the 
methyl group and the alpha-proton.  As a result, two calibration curves were produced.  The 
NAG methyl group calibration curve was used, since the 13C-AcCml signal is also from a 
methyl group.  This calibration curve was also used to confirm 13C-AcCml concentrations in 
subsequent experiments (Fig. 4.22).  
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Figure 4.21. Proton NMR spectrum of mono-acetyl chloramphenicol in CD3CN.  DSS was 
used as a reference.  Left, spectrum of AcCml with chemical shifts indicated.  Right, table of 
expected AcCml proton peaks as described by Derrick and coworkers (Derrick et al., 1992).    
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Figure 4.22.  Calibration curve using 1H,13C-HSQC peak intensities of methyl (CH3) and 
alpha (Cα) carbons from NAG as a function of NAG concentration.  Linear fit line was 
obtained by linear regression in MS Excel.    
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4.4.2 Analysis of chloramphenicol binding by NMR  
 
To determine the dissociation constant (Kd) for the binding of Cml to MdfA, we titrated 
increasing concentrations of MdfA against a constant concentration of 13C-AcCml and 
performed HSQC experiments at each titration point.  We expected to see chemical shift 
perturbations in the peak corresponding to the methyl group of 13C-AcCml, at 2.085 ppm, as 
13C-AcCml was bound by MdfA (Fig. 4.21).  Instead, we observed loss of signal intensity 
corresponding to the increase in concentration of MdfA (Fig. 4.23).  To determine whether the 
observed effects were the result of specific interactions between 13C-AcCml and MdfA, we 
performed these experiments in the presence of excess unlabeled Cml.  Loss of signal intensity 
was much less in competition experiments with unlabeled Cml, and was not seen at all in 
control experiments with detergent (Fig. 4.24). 
Signal intensity loss may be caused by binding of 13C-AcCml to MdfA under conditions 
of slow exchange, or line broadening resulting from fast exchange.  From these data, it is not 
possible to distinguish the two possibilities.  In the case of slow exchange, we would expect 
two peaks, at the chemical shifts corresponding to free ligand, L, and bound ligand, P*L, where 
L refers to ligand and P to protein.  If the signal from P*L is unobservable due to fast relaxation 
(ie. large linewidth), then only the signal from L will be observed, with diminishing intensity as 
protein concentration increases.  On the other hand, if we are actually observing fast exchange, 
L and P*L will have the same chemical shift.  In this case, the only effect that will be observed 
is loss of signal intensity due to linewidth broadening.  The signal-to-noise ratio is insufficient 
to perform accurate line fitting to distinguish between these two possibilities (Fig. 4.23).  As a 
result, we estimated Kd with the assumption that the peak intensity is proportional to the 
fraction of free 13C-AcCml (slow-exchange).  In this case, Kd=[P]*[L]/[P*L]=[Ptotal (Ltotal-
L)]*[L]/(Ltotal-L).  Using this model, Kd of 13C-AcCml was determined to be 10 µM.  More data 
points are required in order to accurately fit the data to a model.  We conclude that affinity 
constants for MDT can be determined by isotope labeling of substrates, but that care must be 
taken to ensure the collection of sufficient data, and to ensure that non-specific interactions to 
detergent are minimized.  
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Figure 4.23. Effect of increasing MdfA concentration on methyl signal from 13C-AcCml 
in the presence and absence of competitor.  A. Addition of MdfA to 13C-AcCml in the 
absence of competitor. B. Addition of MdfA to 13C-AcCml in the presence of competitor 
(1.5 mM Cml).   Methyl signal is indicated by an arrow.  Concentration of total MdfA in 
each spectrum is indicated on right.   
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Figure 4.24. 13C-AcCml binding by MdfA. Blue, MdfA titration in the absence of 
competitor; Green, MdfA titration in the presence of 1.5 mM Cml; and red, detergent 
control. Note that MdfA titration experiments with 13C-AcCml were performed in duplicate 
and the average is shown here.  
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4.5 Initial MdfA crystallization trials 
Following optimization of LMPG and DDM concentrations, we tested the aggregation 
state of MdfA to determine if it was monodisperse, since polydisperse protein samples are not 
suitable for crystallography.  Dynamic Light Scattering  (DLS) experiments were performed on 
MdfA samples in 0.005% LMPG and 0.02% DDM.  DLS experiments show strong light 
scattering at 3 - 4 nm in an 8 mg/mL sample of MdfA in 0.005% LMPG and in a 6.7 mg/mL 
sample of MdfA in 0.02% DDM, typical of a protein molecule of 50 kDa, showing that MdfA 
is monodisperse in these conditions (Fig. 4.25).  These experiments show that MdfA in LMPG 
and DDM at these concentrations can be used for crystal trials.   
 
 
Figure 4.25. DLS experiment of MdfA in 0.005% LMPG and 0.02% DDM.  A. DLS 
experiment of 8.0 mg/mL MdfA in 0.005% LMPG. B. DLS experiment of 6.7 mg/mL 
MdfA in 0.02% DDM. All measurements were taken at 20 °C.  The results show the 
intensity of the light scattered by particles in solution as a percentage of the total mass in the 
sample.   
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To solve the tertiary structure of MdfA, trials were performed to obtain protein crystals 
suitable for X-ray crystallography.  Protein was prepared for crystallization by Ni-NTA 
chromatography in 0.01% LMPG and 0.4% DDM, and was approximately 80% pure.  MdfA in 
0.005% LMPG was not used since mixing with crystal conditions causes the detergent 
concentration to fall below the MdfA solubilization point.  Crystal trials with MdfA in 0.02% 
DDM were not performed due to time considerations. 
High-throughput screening of 1536 conditions at the Hauptman-Woodward Institute at 
23 °C did not yield any hits.  We replicated conditions previously identified in our lab as 
potential crystal hits in a matrix screen; however, they did not yield crystals.  On the other 
hand, it is possible that the phase separation observed under some conditions indicate regions of 
crystallization space to be investigated, since membrane protein crystals tend to appear around 
the phase separation boundary (Fig. 4.26A-C).  Other crystal conditions remained under-
saturated, and indicate that higher precipitant concentrations should be investigated (Fig. 
4.26D).  We performed in-house trials using the MemSys kit (Molecular Dimensions Ltd.), a 
kit that was developed based on reported crystal conditions for membrane protein.  This kit 
covered 48 crystal conditions, and provided a couple of conditions that can be optimized in 
future studies (Fig. 4.26E-F).   
In our opinion, the results here indicate that MdfA crystal trials should continue, but 
should be broadened in scope to include a variety of detergents, temperatures, and co-
crystallization with known substrates.   
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Figure 4.26. Selected in house crystal trials with MdfA in 0.01% (w/v) LMPG and MES 
buffer at 18 °C.  Trials were performed using hanging drop method in 24-well plates.  Phase 
separation is observed in conditions A-C.  An undersaturated drop is shown in panel D.  
Protein precipitation and crystals are observed in conditions E and F. Sample conditions are 
as follows: A. 0.05 CsCl, 0.1 M MES-KOH, pH 6.5, and 30% Jeffamine M-600.  B. 0.1 M 
Sodium citrate/citric acid, pH 5.5, 0.1 M NaCl, and 30% (v/v) PEG 400.  C. 0.1 M Sodium 
Hepes-HCl, pH 7.5, and 30% (v/v) PEG 400.  D. 0.1 M CAPSO-NaOH, pH 9.5, 0.1 M 
NaCl, 0.1 M Li2SO4, and 30% (v/v) PEG 400.  E. 0.1 M Tris-HCl, pH 8.5, 0.1 M NaCl,  0.1 
M MgCl2, and 30% (v/v) PEG 400.  F. 0.1 M Sodium-Hepes-HCl, pH 7.5, 0.1 M NaCl,  0.1 
M MgCl2, and 30% (v/v) PEG 400.  
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5. Discussion 
The aim of this research project was to develop techniques for structural and functional 
characterization of putative multidrug transporters from S. aureus, using a model transporter, 
MdfA.  While the particular details for the characterization of each protein will be different (i.e 
different detergent requirements for solubility, etc.), the overall approach to the study of the 
members of a family of MDT can be the same.  To this end, we developed techniques for 
substrate profile analysis and transport kinetic measurements, and conducted preliminary 
crystallization trials.  MdfA activity in whole cell membranes was confirmed.  An assay that 
monitors proton transport across proteoliposomes by fluorescence was successfully developed.  
Chloramphenicol transport by MdfA was observed, but further optimization of the assay 
conditions is required.  13C isotope labeling of Cml, an MdfA substrate, allowed for Kd 
estimation by NMR by monitoring linewidth broadening associated with specific interactions 
between Cml and MdfA.  However, the data acquired was insufficient to accurately model 
substrate binding by MdfA.  Further experiments, in which binding site saturation is achieved, 
are required.  In addition, detergent screens and optimization using LMPG, DDM, OG, LDAO, 
and C12E8 for use in MdfA crystal trials have been performed and preliminary crystal trials have 
begun.   
5.1 Development of activity assay for MFS multidrug transporters  
 
  An activity assay suitable for testing MFS multidrug transporters had been previously 
developed in our lab (O'Grady, 2010).  This assay monitors substrate/proton counterflow using 
ACMA, a pH-sensitive fluorophore, following generation of a pH gradient using FCCP and 
valinomycin (Fig. 4.10).  We optimized this assay and tested Cml transport by MdfA, but were 
not able to detect MdfA-specific effects.  Given the complexity of characterizing a 
proteoliposome suspension, with no guarantee of results that would explain the observed 
effects, we adopted an alternative approach to test substrate transport. 
 For this assay system, two major questions have to be addressed.  First, how will the 
proton motive force be generated?  Second, what is the optimal reconstitution procedure?  The 
above mentioned assay used valinomycin and FCCP to convert a potassium concentration 
gradient to a proton concentration gradient.  In contrast, we selected the E. coli FoF1 ATPase, a 
powerful proton pump, to generate the energy required for drug transport.  The proton gradient 
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generated was fine-tuned by optimizing the FoF1 ATPase:lipid (w/w) ratio and the amount of 
ATP used.  This system provides several advantages over the valinomycin/FCCP method.  
First, the use of ATP to generate a proton-gradient allows a much greater degree of control of 
the rate and extent of ΔpH, enhancing both the sensitivity of the assay to substrate transport by 
MdfA, and the length of the assay itself.  In addition, passive ion permeability is a major 
challenge with proteoliposomes.  Stimulation of proton accumulation in proteoliposomes by 
valinomycin indicates that the liposomes are able to maintain Δψ and therefore have low non-
specific ion permeability.  We demonstrated proton counterflow coupled to Cml transport in 
membranes from cells overexpressing MdfA.  This counterflow was not observed in 
membranes from cells with background expression level of MdfA.  These results show that 
ΔpH generation by FoF1 ATPase, under these conditions, can be used to test the substrate 
profile of MdfA, and putative MFS MDT.     
 Two popular methods of protein-reconstitution into detergent-disrupted preformed 
liposomes are dialysis and detergent adsorption onto Bio-Beads (Rigaud and Levy, 2003).  We 
tested both methods for co-reconstitution of MdfA and FoF1 ATPase.  While Cml transport by 
MdfA using Bio-Beads for reconstitution was observed, we sought a known universal method 
for the reconstitution of MFS transporters.  We chose dialysis, owing to its reproducibility and 
history of success with MFS transporters (Fig. 4.17) (Poolman and Konings, 1993).  It is very 
likely that the reason why substrate transport was not observed in proteoliposomes reconstituted 
by dialysis is related to DHPC-mediated MdfA inactivation.   
Since reconstitution by dialysis is relatively slow compared to other techniques, it is 
possible that MdfA is denatured during the time required for successful incorporation into the 
liposome.  For these experiments, MdfA was in DHPC micelles.  Since it is known that MdfA 
precipitates in DHPC solution (O'Grady, 2010), the protein samples were carefully handled and 
precipitation was prevented.  However, it is possible that DHPC inactivates MdfA during 
purification.  In previous studies, it has been shown that delipidation by detergents can be 
detrimental for membrane protein activity (Garavito and Ferguson-Miller, 2001).  Added 
evidence for this possibility is provided by the fact that the Cml transport that was observed in 
co-reconstitution experiments using Bio-Beads used MdfA purified using LMPG.  For protein 
reconstitution using the dialysis method, we preferred the use of DHPC due to its higher CMC 
(relative to LMPG), since residual detergent in liposome suspensions can drastically affect 
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transport assays.  However, future studies should test various detergents (e.g. LMPG, DDM, 
and C12E8) to identify a detergent that preserves MdfA activity better than those tested.  That 
detergent could then be successfully applied to putative multidrug transporters from the MFS. 
However, the combined results of substrate transport observed in whole cell membranes 
and proteoliposomes reconstituted using Bio-Beads clearly indicate the need for optimization of 
the assay to enhance sensitivity to substrate transport.  While MdfA confers resistance to a wide 
variety of cytotoxic compounds, the transport rates of these compounds vary.  For example, 
MdfA can confer a 15-fold increase in resistance to Cml, but can only confer two-fold increase 
in resistance to kanamycin (Edgar and Bibi, 1997).  As a result, this assay may not be sensitive 
enough to detect kanamycin transport.  Since the goal of this project is to determine substrate 
profiles of putative MDT, the assay needs to be optimized to be sensitive to substrates with low 
transport rates.  
 
5.2 Determination of substrate binding to MdfA by NMR  
 
 To determine kinetic parameters of substrate binding to MDR transporters, we tested the 
binding of a 13C-labeled substrate to MdfA by NMR.  NMR can be used to study protein-ligand 
interactions by detecting NMR signals of either the isotopically-labeled ligand or protein.  
Selection of which molecule to label is dependent on the purpose of the experiment as well as 
the limitations of NMR spectroscopy.  For example, labeling of the transporter has the 
advantage of providing information both on the affinity for ligand, and which residues are 
involved in ligand binding.  However, for larger proteins, including most membrane proteins, 
overlapping resonances and increased linewidths become major challenges to obtaining well-
resolved spectra useful for kinetic studies (Breeze, 2000; Evans, 1995; Yanamala et al., 2010).  
Prior to this project, extensive NMR studies of MdfA were performed in our lab.  These studies 
all showed extensive signal overlap due to fast relaxation of magnetization, which related to the 
large size of MdfA.  Substrate binding was observed, but extraction of kinetic data was not 
possible (O’Grady, 2010).  On the other hand, ligands are generally small molecules, which 
have much less signal overlap and have narrow linewidths.  In other words, the signal from one 
or several nuclei per molecule is detected instead of the hundreds or more detected in proteins.  
A major disadvantage of the substrate detection method is that experiments are limited to 
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substrates that are available in isotopically labeled form.  Substrates can be labeled with 1H, 
13C, 15N, and 19F by a variety of methods, depending on the substrate source and the 
experimental requirements (Breeze, 2000; Lian and Middleton, 2001; Yanamala et al., 2010).  
Isotopic labeling, especially by non-biological isotopes such as 19F, is usually performed by 
chemical synthesis.  Given these considerations, we labeled Cml with a 13C-isotope for kinetic 
studies.  
Cml contains two hydroxyl groups that can be acetylated by reaction with an acyl halide 
(Derrick et al., 1992).  We were able to distinguish between mono- and di-acetylated Cml by 
thin layer chromatography and NMR, and used mono-acetylated Cml for all experiments.  For 
MDT with large, flexible substrate-binding pockets, the addition of an acetyl group is not likely 
to cause large changes in binding kinetics.  However, 13C has 1.1% natural abundance; as a 
result, even with isotope-editing techniques such as HSQCs, care has to be taken to ensure that 
naturally occurring 13C atoms, for example from detergent molecules, do not interfere with the 
reporter group signal.  Less frequently occurring NMR-active isotopes, such as 15N, or 19F, 
which has 100% natural abundance, but does not occur naturally in biological systems, can be 
of benefit in this regard.  In particular, 19F has the added benefit of having high sensitivity to 
detection in NMR, and can be detected directly (Yanamala et al., 2010).  It is also extremely 
sensitive to its chemical environment, providing evidence for substrate-protein interactions 
where 13C and 15N do not (Gerig, 2001; Yanamala et al., 2010).  However, we chose 13C 
labeling of Cml because it combines a sufficient level of detection with ease of chemical 
synthesis.  
Linewidth broadening of the reporter signal was determined by measuring peak 
intensity changes.  However, it was not possible to fit the data collected to a model of substrate 
binding: an improved signal-to-noise ratio is required, combined with data points in the 
saturation range of the substrate binding curve.  As a result, we estimated Kd with the 
assumption that the decrease in peak intensity is proportional to the amount of free ligand in 
solution, and obtained a Kd on the order of 10 µM.  These experiments will need to be repeated 
in the future.    
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5.3 Detergent selection for structural studies and development of conditions for 
crystallization trials 
 The purification protocol previously developed for MdfA was reproduced to a yield of 
0.9 mg protein/L cell culture, and ~80% purity (O’Grady, 2010).  This yield is low compared to 
that generally required for structural studies, even when compared to membrane proteins.  For 
example, the final yield from GlpT expression and purification was 1.8 mg protein/L cell 
culture (Auer et al., 2001).  However, scaling up of protein production to 6 L per purification 
provides a useable amount of protein (~6 mg) for crystal trials.  Protein sample purity, on the 
other hand, does require improvement.  For crystal trials, protein purity of 98% is 
recommended, but samples of lower purity can be used.  We were unable to improve protein 
homogeneity by using imidazole gradient elution in Ni-NTA chromatography.  Future studies 
could use size-exclusion chromatography to improve the likelihood of successful trials (Newby 
et al., 2009).   
Purification protocols had been previously developed for MdfA in 0.2% LMPG, 0.4% 
DHPC and 0.4% DDM (w/v) (O'Grady, 2010).  MdfA was found to be monodisperse in all 
three detergents, a condition necessary for structural studies (Carpenter et al., 2008; Garavito, 
1996; O'Grady, 2010).  However, these detergent concentrations are well above their respective 
CMCs, and MdfA is not stable in DHPC micelles (O'Grady, 2010).  Since the usual working 
range of detergents is 2-3 times the CMC, and detergent micelles lead to weak crystal contacts, 
it is important to optimize the detergent concentration used in structural studies (Garavito, 
1996; Hunte and Michel, 2002; Iwata, 2003).  In addition, it is important to test a variety of 
detergents for suitability in crystal trials, in order to improve the likelihood of obtaining a 
protein crystal (Iwata, 2003).   
MdfA solubility in OG, LDAO and C12E8 was investigated, and the concentrations of 
LMPG and DDM optimized.  MdfA was determined to be soluble in 0.005% LMPG, 0.02% 
DDM and 0.013% C12E8, but not in 1.75% OG and 0.07% LDAO.  The aggregation state of 
MdfA in LMPG and DDM was investigated by dynamic light scattering, and MdfA was found 
to be monodisperse at concentrations suitable for structural studies.  These results are not 
surprising, given that, though OG and LDAO have been successfully used in structural studies, 
they are relatively harsh detergents, especially prone to denaturing α-helical proteins (Privé, 
2007).  On the other hand, DDM and C12E8 are mild detergents that have been successfully 
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used to crystallize MFS transporters, including GlpT, LacY, and EmrD (Abramson et al., 2003; 
Huang et al., 2003; Privé, 2007; Yin et al., 2006).  Finally, while LMPG is particularly known 
for its use in NMR studies, it should not be excluded from use in crystal trials, since, in general, 
conditions that produce good NMR spectra also favor protein crystallization (Patching, 2011; 
Privé, 2007; Wiener, 2004). 
The initial crystal trials started here have been by no means exhaustive.  First, screens 
have only been performed using LMPG and non-optimal concentrations of DDM.  These now 
have to be performed with the optimal concentration of DDM and with C12E8.  Second, the 
effects of temperature, buffer conditions, and detergent and protein concentration have not been 
systematically tested.  Finally, it must be mentioned that though detergent phase separation in 
crystal often leads to protein precipitation and is generally avoided by membrane structural 
biologists, membrane protein crystals preferentially appear at the phase boundary, due to the 
attractive interactions between detergent micelles (Garavito, 1996; Hunte, 2003; Koszelak-
Rosenblum et al., 2009; Newby et al., 2009).  Phase separation is detergent-specific and 
affected by even small changes in additives, temperature, or precipitant (Garavito and 
Ferguson-Miller, 2001).  As a result, we have opted to select conditions where phase separation 
is observed for further investigation (Fig 4.26A) (Koszelak-Rosenblum et al., 2009).   
In addition, the conformational flexibility of MFS proteins must be taken into account.  
Mutants of MdfA that are less conformationally flexible should be identified and submitted to 
crystal trials.  Co-crystallization with substrates such as EtBr and Cml, respectively, should also 
be attempted.  Decreasing conformational flexibility and co-crystallization with substrate was 
essential for successful crystallization of LacY (Abramson et al., 2003).  The relatively tight 
binding of Cml measured in NMR studies favors this approach. 
 
6. Conclusions and future directions 
6.1 Conclusions 
 
MdfA purification in LMPG, DDM, and C12E8 was optimized for use in crystal trials.  
Initial screens were performed using LMPG and DDM, but have not yet yielded protein crystals 
suitable for structural studies.  The activity of MdfA in whole cell membranes was confirmed.  
An assay to test substrate transport of purified MdfA reconstituted in proteoliposomes was 
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developed, and validated in whole cell membranes.  Substrate transport in MdfA and FoF1 
ATPase co-reconstituted proteoliposomes was also observed.  However, reproducible substrate 
transport was not observed.  It was determined that NMR can be used to study the kinetics of 
substrate binding to MdfA by substrate isotope labeling, and isotope editing techniques.  More 
data is required to accurately measure the Kd.  However, these studies clearly show that NMR 
can be used to determine kinetic data for MFS multidrug transporters. 
6.2 Future directions  
 Our aim was to develop techniques for structural and functional characterization of 
putative multidrug transporters from S. aureus, using a model transporter, MdfA.  Co-
reconstitution conditions should be more thoroughly investigated to enhance sensitivity of the 
assay for use in studies of putative transporters.  MdfA purified in LMPG, DDM and C12E8, 
respectively, should be reconstituted into proteoliposomes with FoF1-ATPase, and its Cml 
transport activity investigated.   Dialysis conditions, such as temperature and duration should be 
optimized.  Finally, the effect of freeze/thaw cycles on MdfA reconstitution and activity can be 
investigated.   
As mentioned, NMR experiments to confirm the Kd of AcCml binding to MdfA must be 
performed.  Other MdfA substrates should be labeled, either with 13C or other isotopes such as 
15N or, ideally, 19F, and the kinetics of binding to MdfA investigated.  Doing so will develop a 
bank of NMR experiments, and potential substrates, that can and should be used to test putative 
MDT.   
The optimized LMPG and DDM concentrations should be used for crystal trials of 
MdfA.  The aggregation state of MdfA in other detergents should be tested.  Co-crystallization 
of MdfA and substrates such as EtBr and Cml should be performed.  These studies should all be 
performed at both 4 and 18 °C.  MdfA purity can be improved by size exclusion 
chromatography, and should be attempted if crystal trials do not yield suitable hits.  MdfA 
mutants with reduced conformational flexibility should be generated and submitted to crystal 
screens.  These mutants can be tested for Cml transport ability in whole membrane assays, and 
for substrate binding in NMR experiments.  
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